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There is clear evidence that alcohol consumption is a risk factor for several 
cancers in humans. Ethanol is not carcinogenic as a molecule, but there is 
conclusive evidence that acetaldehyde, formed by microbial metabolism of 
ethanol in the upper digestive tract, acts there as a local carcinogen. 
Acetaldehyde is found in varying concentrations in alcoholic beverages and 
also in foods. This acetaldehyde could contribute to overall acetaldehyde 
exposure in the upper digestive tract. Consumption of calvados has been 
linked to an increased risk for oesophageal cancer in France. Achlorhydric 
gastritis is a premalignant condition, in which gastric bacterial overgrowth can 
lead to increased acetaldehyde concentrations in the stomach after ethanol 
ingestion. L-Cysteine binds to acetaldehyde and can be used to lower 
acetaldehyde concentrations possibly reducing acetaldehyde exposure, and 
the carcinogenic effects thereof. 
Aims 
The first and second aim of this thesis was to examine acetaldehyde 
concentrations in calvados and other alcoholic beverages, and to study the 
exposure to acetaldehyde after a sip of these beverages. The third aim was to 
develop and test a slow-release L-cysteine formulation for eliminating 
carcinogenic acetaldehyde in achlorhydric stomach during ethanol exposure. 
Methods 
Firstly, farm-made calvados was collected in Normandy, France. Ethanol and 
acetaldehyde concentrations were measured and compared to samples of 
commercially available alcoholic beverages. Secondly, salivary acetaldehyde 
concentrations were measured after small sips of alcoholic beverages. 
Calvados with high acetaldehyde concentration was compared to ethanol of 
similar concentration without acetaldehyde. Thirdly slow-release L-cysteine 
capsules were formulated and given to volunteers with achlorhydric gastritis 
prior to infusion of dilute ethanol through nasogastric intubation. Samples of 




Results and conclusions 
We found 42% higher mean acetaldehyde concentrations in farm-made and 
industrially manufactured calvados when compared to other alcoholic 
beverages.  Markedly elevated concentrations of acetaldehyde were found to 
be produced from ethanol in the oral cavity instantly after a small sip of 
alcoholic beverage, and that the exposure continued for at least 10 minutes. 
Acetaldehyde present in the beverage had a small, short-term increasing effect 
on total acetaldehyde exposure. Furthermore, we found that L-cysteine can be 
used to decrease acetaldehyde concentration to less than half in gastric juice 
after ethanol ingestion in test subjects with achlorhydric gastritis. 
 
Acetaldehyde produced microbially from ingested ethanol is probably the 
main source for carcinogenicity of ethanol in upper digestive tract, although 
acetaldehyde in beverages contributes slightly to overall acetaldehyde 
exposure. This could explain the increased risk for oesophageal cancer 
associated with consumption of hot calvados. Slow-release L-cysteine capsules 







The WHO estimates that there were 14.1 million new cancer cases, 8.2 million 
cancer deaths and 32.6 million people living with cancer (within 5 years of 
diagnosis) in 2012 worldwide. The worldwide risk of getting vs. dying of cancer 
before the age of 75 is 18.5% vs. 10.4%, respectively (IARC 2018). Alcohol 
consumption increases the risk of oral, pharyngeal, laryngeal, oesophageal, 
gastric, liver, colorectal and female breast cancer (Boffetta, Hashibe 2006, 
Bagnardi et al. 2015).  It has been estimated that globally 5.5% of all cancers 
(7.2% in men, 3.5% in women) are attributable to alcohol drinking (Praud et 
al. 2016). 
 
In western Europe the figures are somewhat higher. Data from the 
prospective cohort study EPIC (The European Prospective Investigation into 
Cancer and Nutrition) showed that among men and women 10% and 3% of the 
incidence of all cancers were attributable to former and current alcohol 
consumption. The figures were even higher for selected cancers, 44% vs. 25% 
for upper aerodigestive tract cancer, 33% vs. 18% for liver cancer and 17% vs. 
4% for colorectal cancer, for men and women respectively, and 5% for female 
breast cancer. The risks for all cancers related to alcohol consumption 
increased in a dose-dependent manner, with no lower limit below which the 
risk of cancer is decreased (Schutze et al. 2011). Accordingly, in a meta-
analysis by Bagnardi et. al. even light drinking up to 1 drink/day compared to 
non-drinking is associated with a relative risk ratio of 1.17 for oropharyngeal, 
1.30 for oesophageal squamous cell carcinoma and 1.05 for female breast 
cancer (Bagnardi et al. 2013). 
 
In conclusion, alcohol drinking is associated with an increased risk for 
cancer, with no safe lower limit of consumption. There have been reports of 
increased cancer risk from certain types of alcoholic beverages, one of which 
gave the idea for the first original publication in this thesis (Launoy et al. 1997). 
However, analysis of epidemiological data available shows little indication that 
the carcinogenic effects of alcohol drinking depends on the type of beverage 
and it is concluded that ethanol itself is the determinant (IARC Working Group 
on the Evaluation of Carcinogenic Risks to Humans 2012).  
 
As ethanol itself is not mutagenic the mechanism of carcinogenesis 
associated with alcohol drinking has to date not been fully elucidated. There is 
strong evidence that points to acetaldehyde, the first metabolite of ethanol, 
being the key ingredient in aerodigestive tract carcinogenesis (IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans 2012). 
Acetaldehyde is formed from ethanol locally in the upper digestive tract mainly 
by microbes representing normal oral flora (Homann et al. 1997). 
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Acetaldehyde is also present in varying amounts in different alcoholic 
beverages (Lachenmeier, Sohnius 2008). Furthermore, acetaldehyde is 
formed from ethanol in the achlorhydric stomach of test subjects with atrophic 
gastritis (Vakevainen et al. 2002), and also in healthy volunteers (Maejima et 
al. 2015). 
 
The aims of this study were to investigate acetaldehyde content of different 
types of calvados, especially farm made calvados, and to determine the effect 
of sipping alcoholic beverages with different acetaldehyde content on salivary 
acetaldehyde concentration. Also, we wanted to determine whether L-cysteine 
can be used to deactivate carcinogenic acetaldehyde formed from ethanol in 
achlorhydric stomach. 
Review of the literature 
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REVIEW OF THE LITERATURE 
Alcohol drinking and cancer - epidemiology  
Oral and pharyngeal cancer 
The IARC has summarized the data available on alcohol drinking and cancer 
up to 2009. Alcohol consumption increases the risk for oropharyngeal cancer 
in a dose-dependent manner. (IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans 2012). In a meta-analysis covering case-control 
and cohort studies up to October 2010 the risk ratio in non-smokers was 1.05-
1.67 (95% CI) for drinking and 1.80-3.58 for heavy drinking (≥ 4 drinks/day). 
Concurrent smoking clearly increases the RR to 2.31-3.70 for overall drinking 
and 5.05-7.90 for heavy drinking. No significant difference in risk ratios for 
consumers of different types of beverages was found  (Turati et al. 2013.). The 
type of beverage most frequently consumed within a population is usually the 
one associated with the highest risk (Boffetta, Hashibe 2006). The RR for light 
drinking (≤1 drink daily) was 1.17; 95% CI, 1.06-1.29 for oropharyngeal cancer 
(Bagnardi et al. 2013). 
 
In a multicentre European case-control study, smoking and alcohol 
drinking were the most important risk factors for oropharyngeal cancer, with 
a population-attributable ratio (PAR) of 73.9% combined. The PAR was 0.3% 
for alcohol alone, 29.7% for smoking alone and 44.1% for alcohol drinking and 
smoking combined (Anantharaman et al. 2011). The EPIC study estimates a 
RR of 1.09; 95% CI, 1.06-1.12 (men) vs. 1.26; 95% CI, 1.07-1.49 (women) per 
every 10g daily increase in lifetime alcohol intake, when adjusted for smoking, 
and other life habits such as education, fruit and vegetable intake, body mass 
index and never- and former drinkers (Weikert et al. 2009). 
 
Long-term frequent use of mouthwash – which typically contains alcohol 
in the order of 20% - is also associated with an increased risk for oral cancer 
(OR 1.28; 95% CI, 1.06-1.56 for use more than 35 years.) (Boffetta et al. 2015). 
Laryngeal cancer 
RR for laryngeal cancer was estimated at 2.65; 95% CI, 2.19-3.19 for heavy 
drinkers vs. non- or occasional drinkers in a recent comprehensive meta-
analysis (Bagnardi et al. 2015). Again, the most frequently consumed alcoholic 
beverage tends to yield the highest risk in a population (IARC Working Group 
on the Evaluation of Carcinogenic Risks to Humans 2012). Light consumption 
of alcohol was not associated with a risk for laryngeal cancer (Bagnardi et al. 
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2013). In the EPIC study the dose dependence was estimated to a RR adjusted 
for smoking and other life habits of 1.08; 95% CI 1.05-1.12, for men and 1.32; 
95% CI, 0.93-1.89 for women per every 10g daily increase in lifetime alcohol 
consumption (Weikert et al. 2009). Population attributable ratio of 
hypopharyngeal / laryngeal cancer was 0.02% for alcohol alone, 36.1% for 
smoking alone and 48.1% for alcohol drinking and smoking combined 
(Anantharaman et al. 2011). 
Oesophageal cancer 
Oesophageal cancer presents as squamous cell cancer (SCC) and 
adenocarcinoma (AC). The former of these is clearly associated with alcohol 
consumption. Bagnardi estimates the RR for oesophageal SCC at 1.26; 95% CI, 
1.06-1.50 for light drinkers, 2.23; 95% CI, 1.87-2.65 for moderate drinkers and 
4.95; 95% CI, 3.86-6.34 for heavy drinkers. The same data shows no risk from 
alcohol consumption for oesophageal AC or gastric cardia cancer. RR were 
0.86; 95% CI,0.76-0.98, 0.97; 95% CI, 0.78-1.22 and 1.15; 95% CI, 0.95-1.39 
respectively (Bagnardi et al. 2015). Dose dependence when adjusted for 
smoking and other life habits was estimated at RR for oesophageal SCC of 1.18; 
95% CI, 1.10-1.27   and 1.35; 95% CI, 1.13–1.60 for men and women, 
respectively, per every 10g increase in daily alcohol intake (Weikert et al. 
2009).  
 
Oesophageal SCC is more common than AC in most populations with a 
ratio of 34:1 in African Americans to 1:1 in South Australian men. An increase 
in the incidence of AC has been observed, whereas the incidence of SCC has 
remained stable.  The increase of AC has been attributed to an increase in 
obesity and gastrointestinal reflux (Vizcaino et al. 2002). 
 
The risk factors for oesophageal SCC are tobacco use, alcohol consumption, 
mutations in enzymes that metabolise alcohol, achalasia, caustic injury, 
history of thoracic radiation, low socioeconomic status, poor oral hygiene, 
nutritional deficiencies, and non-epidermolytic palmoplantar keratoderma. 
Only a few of these are shared risk factors for oesophageal AC.  The risk factors 
for oesophageal AC include symptomatic gastro-oesophageal reflux disease, 
Barrett´s oesophagus, obesity, tobacco use, history of thoracic radiation, diet 
low in vegetables and fruits, increased age, male sex, medications that relax 
the lower oesophageal sphincter, and rarely familial history (Pennathur et al. 
2013). Pernicious anaemia and atrophic gastritis is also a risk factor for 
oesophageal SCC (Islami et al. 2011, Ye, Nyren 2003). 
 
Drinking cessation leads to a slow decrease in oesophageal cancer risk, and 
it has been estimated that 16 years is required until all elevated risk has 
disappeared (Jarl, Gerdtham 2012). 
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Part of this thesis was inspired by discovery of an association between hot 
calvados and oesophageal cancer. When investigating regional differences in 
the incidence of oesophageal cancer in France it was found that consumption 
of hot calvados (as grog with hot water, or with hot coffee) was associated with 
an increased risk for oesophageal squamous cell cancer, when adjusted for life 
habits and socioeconomic status and consumption of other alcoholic 
beverages (OR = 2.33 for 41g alcohol / week; 95% CI, 1.12-4.87) (Launoy et al. 
1997). Yet again in most studies the beverages most commonly consumed were 
associated with the highest risk for oesophageal cancer (IARC Working Group 
on the Evaluation of Carcinogenic Risks to Humans 2012). 
 
In the meta-analysis by Chen et. al. consumption of hot beverages and 
foods was also associated with oesophageal cancer, specifically SCC (OR 1.60; 
95% CI, 1.29-2.00), and not AC (OR: 0.79; 95%CI, 0.53-1.16) There was 
however no significant association in a European population (OR 0.95; 95%CI, 
0.68-1.34), whereas risks were significant in an Asian population (OR 2.06; 
95% CI, 1.62-2.61) and a South American population (OR 1.52; 95% CI, 1.25-
1.85) (Chen et al. 2015). 
Gastric cancer 
Helicobacter Pylori infection is the single most important risk factor for 
gastric cancer accounting for between 65-80% of non-cardia gastric cancers 
(Helicobacter and Cancer Collaborative Group 2001). The association between 
alcohol consumption and gastric cancer is not as clear as in other upper 
digestive tract cancers. The IARC concluded in 2012 that data on the 
association of alcohol drinking and gastric cancer is inconsistent, and pointed 
out that in no studies was it possible to adjust fully for lifetime infection with 
H. Pylori (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans 2012).  
 
In a study from South Korea drinking ≥ 7 times a week or drinking ≥ 55g 
alcohol per occasion was associated with an increased risk for gastric cancer 
in H. Pylori negative individuals (OR 3.48; 95% CI, 1.13-10.73 and 3.27; 95% 
CI, 1.01-10.56), whereas there was no increased risk in H. Pylori positive 
individuals (OR 1.17; 95% CI, 0.78-1.77 and 0.94; 95% CI, 0.61-1.46). It is 
noted that the No. of cancer cases in the H. Pylori negative group was only 31 
vs. 235 in the H. Pylori positive group (Ma, S. H. et al. 2015). 
 
There is also evidence of an increased risk for gastric cancer associated with 
allelic variants in the ADH1 gene cluster from the EPIC data, and the risk was 
accentuated by increased alcohol, and especially beer consumption (Duell et 





Light or moderate alcohol drinking does not seem to be a risk factor for 
gastric cancer. A meta-analysis of available data from 2012 with 44 case-
control, and 15 cohort studies estimated the RR at 1.07; 95% CI, 1.01-1.13 for 
alcohol drinkers vs. non-drinkers, and at 1.20; 95% CI, 1.01-1.44 for heavy 
drinkers (Tramacere et al. 2012).  
 
In a more recent meta-analysis by Ma et al. including 10 case-control 
studies an increased risk for gastric cancer was found when compared to non-
drinkers for moderate drinkers (OR 1.30; 95%CI, 1.13-1.50) and heavy 
drinkers (OR 1.58; 95%CI, 1.21-2.05). Moderate drinking was defined as 15 
grams a day for women, and 30 grams a day for men. Heavy drinking was 
defined as more than 30 grams alcohol a day for both genders. It is not clear 
from the paper in what category women drinking between 15, and 30 grams 
daily fall (Ma, K. et al. 2017). There are other serious issues with this paper, as 
some of the odds ratios, and numbers of cases and controls differ from the 
ones in the original papers included in the meta-analysis. (Ji et al. 1996, Shin 
et al. 2011, Zaridze et al. 2000) Some of the papers, or even journals referenced 
could not be found for verification of data. 
 
In another meta-analysis of 22 cohort studies no significant association was 
found between gastric cancer and light or moderate alcohol consumption. 
Heavy alcohol consumption (<24g/day) was associated with an increased risk 
for gastric cancer (OR 1.13; 95%CI 1.06-2.21). Female light drinkers <12g/day 
were at a lower odd for gastric cancer compared to non-drinkers (OR 0.74; 
95%CI 0.57-0.98)(He et al. 2017). 
 
A recent pooled analysis of epidemiological studies found no increase in 
gastric cancer risk in those who consumed up to four alcoholic drinks per day, 
whereas risk was increased in those who consumed from >4 to 6 drinks/day 
(OR 1.26; 95% CI, 1.08–1.48) and those who consumed >6 drinks/day (OR 
1.48; 95% CI 1.29–1.70). Unlike in the Korean study mentioned above, the 
increased risk associated with heavy alcohol consumption was similar between 
H. Pylori positive and negative individuals (Rota et al. 2017). 
 
Another meta-analysis of prospective cohort studies on dietary factors 
associated with risk of gastric cancer showed an association between alcohol 
overall (OR 1.15; 95%CI, 1.01-1.31), beer (OR 1.21; 95%CI, 1.02-1.43), and 
liquor (OR 1.22; 95%CI, 1.05-1.43), and gastric cancer.  Consumption of wine 
was not associated (OR 1.02; 95%CI, 0.77-1.34) (Fang, X. et al. 2015). 
 
It is concluded from the above that alcohol consumption increases the risk 
for upper gastrointestinal tract cancers in a dose-dependent manner. The 
effect is strongest in oral, pharyngeal and oesophageal cancer, and somewhat 
lesser in laryngeal cancer, and lowest in gastric cancer. 
Review of the literature 
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Gene polymorphisms and upper gastrointestinal tract 
cancers 
Polymorphisms in genes encoding enzymes that are involved in metabolizing 
alcohol are associated with different risks for upper aerodigestive tract 
(UADT) cancers. Consumed alcohol is metabolized in the liver by alcohol 
dehydrogenase (ADH) to acetaldehyde, which is then metabolized by aldehyde 
dehydrogenase (ALDH) to harmless acetate. Several subtypes of these 
enzymes exist, but the most studied ones are ADH1B (previously known as 
ADH2) and ADH1C (ADH3) and ALDH2. Knowledge about the genetic 
expression and activity of these various enzyme subtypes in upper digestive 
tract, and salivary gland mucosa is thus far short of drawing the full picture of 
local acetaldehyde formation.  
ADH1B 
The ADH1B*1 allele is the predominant allele in most populations, whereas 
ADH1B*2 is associated with an approximately 40 times faster metabolic 
activity for ethanol in vitro (Bosron, Li 1986). This fast allele is commonly 
found in western and eastern Asian populations, but in under 10-15% of 
European, African and American populations (Li, H. et al. 2007).  
 
In a recent meta-analysis, it was summarized that the ADH1B*1/*1 allele is 
a moderate risk factor for UADT cancers compared to the ADH1B*2/*2 allele 
in non-drinkers (ref.) (OR 1.78; 95% CI, 1.02-3.08).  Alcohol drinking 
increases the risk for UADT cancer in the ADH1B*2/*2 to OR 3.36; 95% CI, 
2.65-4.27 compared to ref. Furthermore, the risk is clearly increased in the 
predominant ADH1B*1/*1 genotype carrying alcohol drinkers (OR 18.48; 95% 
CI, 12.95-26.40) compared to non-drinkers with ADH1B*2/*2 genotype (ref.) 
(Guo et al. 2012). In conclusion, the faster in vitro ADH1B*2 is associated with 
a decreased cancer risk. It has been suggested that this is due to faster 
elimination of ethanol from the systemic circulation, or by decreasing overall 
alcohol consumption(Chang et al. 2012). 
 
No information on the cancer risk associated with the ADH1B*3 allele, 
which is found in 25% of the African population, was found in the literature. 
ADH1C 
Two alleles are known to exist of the ADH1C gene. ADH1C*1 encodes for a fast 
ADH1C in vitro, with an approximately 2.5-fold capacity for ethanol oxidation 
(Bosron et al. 1993). In a pooled analysis of 7 case-control studies with 1325 
cases and 1760 controls there was no risk difference for head and neck cancer 
observed between ADH1C *1/*1, *1/*2 and *2/*2 genotypes. (Brennan et al. 
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2004). In a study focusing on heavy drinkers an increased risk for homozygous 
genotype ADH1C*1/*1 was observed for oesophageal, hepatocellular, and head 
and neck cancer. (OR 2.93; 95%CI, 1.84–4.67, 3.56; 95%CI, 1.33–9.53 and 2.2; 
95%CI, 1.11–4.36, respectively) (Homann et al. 2006). A meta-analysis 
including 23 studies worldwide found slightly lower odds ratios (0.87; 95%CI 
0.76 - 0.99) for head and neck cancers in ADH1C*1 homozygotes combined 
with ADH1C*1/*2 vs. ADH1C*2 homozygotes(Chang et al. 2012). 
 
In Caucasian populations both homozygotic alleles are equally common, 
with 50-70 percent carrying the heterozygous ADH1C*1/*2 genotype, whereas 
in Asians the ADH1C*2/*2 genotype was rare (Brennan et al. 2004). Salivary 
acetaldehyde concentration after ethanol ingestion ad libitum was  twofold in 
healthy volunteers homozygous for ADH1C*1 when compared to subjects with 
ADH1C*1/*2 or ADH1C*2/*2 genotype (Visapaa et al. 2004).  
 
In conclusion, the faster in vitro ADH1C*1 is related to higher salivary 
acetaldehyde concentrations. The overall effect of this genotype seems to be 
protective of head and neck cancers, but in heavy drinkers there is some 
evidence pointing to an increased UADT cancer risk possibly due to elevated 
salivary acetaldehyde concentrations during drinking. 
ALDH2 
A mutation in the ALDH2 gene which is found almost exclusively in people of 
East Asian descent encodes for an inactive ALDH2 enzyme (Harada et al. 1981, 
Li, H. et al. 2009). The enzyme is inactive in homozygotes, whereas 
heterozygotes retain 17% of activity in liver tissue (Lai et al. 2014). It was first 
reported in 1996 that this mutation is linked to an increased risk for 
oesophageal cancer among alcoholics and heavy drinkers(Yokoyama, A. et al. 
1996). On the other hand, the inactive form of this enzyme also protects from 
alcoholism, due to a ”flushing reaction”, an adverse reaction to even a small 
amount of ingested alcohol due to accumulation of acetaldehyde. 
Heterozygotes are capable of heavy drinking, but homozygotes are essentially 
unable to drink heavily. (Peng et al. 1999). OR for alcohol dependence in 
carriers of the ALDH2*2 gene was 0.22; 95%CI 0.18-0.27 in a pooled meta-
analysis (Li, D. et al. 2012). 
 
Homozygotes for ALDH2*2 are practically unable to consume alcohol, and 
they have a lower risk for oesophageal cancer, (OR = 0.36; 95%CI 0.16-0.80) 
when compared to ALDH2*1 homozygotes. However, ALDH2*1/*2 carried an 
increased risk for oesophageal cancer, when compared to ALDH2*1/*1 (OR = 
3.19; 95%CI 1.86-5.47). Among heavy drinkers the risk was further increased 
(OR = 7.07; 95%CI 3.67-13.60), whereas there was no increased risk in non-
drinkers (OR= 1.31; 95%CI 0.70-2.47) (Lewis, Smith 2005).  
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Similar figures were found for heterozygotes in a more recent meta-
analysis. The risk for oesophageal cancer in ALDH2*1/*2 vs. *1/*1 was 1.28; 
95%CI 0.91-1.80 vs. 3.12; 95%CI 1.95-5.01 vs. 7.12; 95%CI 4.67-10.86 in 
never/rare drinkers, moderate drinkers and heavy drinkers respectively.  
ALDH2*2/*2 homozygotes had similar risk for oesophageal cancer in 
never/rare drinkers compared to ALDH2*1/*1 homozygotes (OR = 1.08; 
95%CI 0.48-2.44), whereas an increased risk was observed in moderate and 
heavy drinkers combined (OR = 4.42; 95%CI 1.72-11.36), it is noted that the 
authors pooled never/rare drinkers and moderate/heavy drinkers in this 
analysis due to small number of drinkers in ALDH2*2/*2 group.  (Yang et al. 
2010).  
 
Less data is available for oral/oropharyngeal cancer and ALDH2 genotype, 
but available data points to an increased risk associated with the inactive 
ALDH2*2 allele. In a small case-control study among Japanese alcoholics with 
33 cases and 476 controls, risk for oropharyngeal cancer among ALDH2*1/*2 
heterozygotes was greatly increased compared to ALDH2*1/*1 homozygotes 
(OR 18.52; 95%CI 7.72-44.44)  (Yokoyama, A. et al. 2001).  In a Japanese 
overall population with 147 cases and 92 controls, no significant association 
between ALDH2 genotype or alcohol drinking and oral cancer was found 
(Katoh et al. 1999). Another study with, with 114 cases and 33 controls, all who 
were alcohol drinkers, showed an increased risk for oral cancer in 
ALDH2*1/*2 heterozygotes (OR = 2.9; 95%CI 1.1-7.8) (Nomura et al. 2000). 
In a meta-analysis including six studies, 945 cases, and 2917 controls the OR 
for head and neck cancer was 0.53; 95%CI 0.28-1 for ALDH2*2/*2 and 1.83; 
95%CI 1.21 – 2.77 for *1/*2 compared to *1/*1 (Boccia et al. 2009).  
 
A case-control study on the interplay of the genetic variants of ALDH2 and 
ADH1B and oral hygiene in the risk of head and neck cancer showed again an 
increased risk for head and neck cancer in association with slower 
ALDH2*1/*2 (OR 1.89; 95%CI 1.36 – 2.62) when compared to normal 
ALDH2*1/*1. The completely inactive ALDH2*2/*2 was not a risk factor (OR 
1.20; 95%CI 0.62 – 2.32). The slow ADH1B*1/*1 was also associated with an 
increased risk (OR 2.08; 95%CI 1.14-3.80) compared to fast ADH1B*2/*2. The 
risk was further increased in these subgroups with increased alcohol 
consumption. In ALDH2 deficient individuals OR was 2.6; 95%CI 1.19-5.75 for 
moderate drinking (up to 50g/day), and 7.28; 95%CI 2.00-26.74) for heavy 
drinking. In ADH1B deficients OR for HNC was 2.72; 95%CI 1.43 – 5.17 for 
heavy drinking (>50g/day)(Tsai et al. 2014). 
 
The risk for stomach cancer was also increased in ALDH2-deficient 
individuals in a Japanese case control study with 697 cases of stomach cancer 
and 1372 non-cancer control subjects. OR for stomach cancer in ALDH2-
deficients was 1.40; 95%CI 1.11-1.76 in heterozygotes, and 1.73; 95%CI 1.12-
2.68 in homozygotes. ALDH2-deficiency combined with heavy drinking 
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increased the odds ratio to 3.03; 95%CI 1.59-5.79 (Matsuo et al. 2013). Further 
evidence for the role of acetaldehyde in gastric cancer was provided by a study 
wherein interaction between heavy alcohol drinking, ALDH2 deficiency, and 
atrophic gastritis resulted in a substantially increased risk for gastric cancer 
(OR 3.92; 95%CI 6.4-239) (Yokoyama, A. et al. 2007). 
Ethanol metabolism 
Absorption and distribution 
There is no transport mechanism for ethanol, which is freely absorbed into the 
water phase of the body. Ethanol is insoluble in fats and oils, although it passes 
readily through biological membranes through diffusion. The stomach and 
small intestine are the primary sites for ethanol absorption. Blood flow helps 
to distribute ethanol into all tissues and fluids, until an equilibrium 
concentration is achieved which depends on the relative water content of 
tissues. Ethanol concentrations in blood, saliva, and upper digestive tract 
contents is essentially equal at equilibrium (Cederbaum 2012, Halsted et al. 
1973, Jones 1979). 
 
After ingestion, first pass metabolism of ethanol by the gastric mucosa and 
liver accounts for a varying amount of ethanol metabolism, decreasing the 
bioavailability of ethanol when compared to intravenous administration. First 
pass metabolism increases with delayed gastric emptying (Oneta et al. 1998). 
Hepatic and gastric first-pass metabolism are not easily distinguished from 
each other, and the proportion in which they contribute to first pass 
metabolism of ethanol is unclear. Estimates for contribution of first pass 
metabolism of ethanol ranges from 1-20% of total ethanol metabolism (Seitz, 
Poschl 1997). 
Metabolism 
Ethanol elimination is primarily by metabolism, and only minute amounts are 
excreted in breath, urine and sweat (~1%) (Holford 1987). The liver is the 
primary organ for ethanol metabolism, but significant extrahepatic 
metabolism, up to 40-55%, occurs especially in cirrhosis (Utne, Winkler 1980, 
Dam et al. 2009). Three distinct pathways for ethanol metabolism are known. 
In each pathway, ethanol is oxidized to acetaldehyde which is further oxidized 
to acetate. Acetate can then be converted to acetyl-coenzyme A, which is freely 
used by the body to produce Co2, fatty acids, ketone bodies, or 
cholesterol(Cederbaum 2012). 
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Alcohol dehydrogenase 
Alcohol dehydrogenases catalyse the oxidation of a wide range of alcohols, 
protecting cells from toxic effects of various alcohols. Six vertebral classes of 
alcohol dehydrogenase are known to exist (I-VI). ADH:s are cytoplasmic 
enzymes. Class I (ADH1A, ADH1B, and ADH1C) is the principal alcohol 
dehydrogenase present in liver tissue, and to lesser extent in other tissues. 
Class II ADH2 which is also present in liver has a higher Km for ethanol than 
Class I ADH1, and thus only participates in higher concentrations of ethanol. 
Class IV ADH4 is present in the upper aerodigestive tract, and stomach, and 
probably accounts for the gastric first pass metabolism of ethanol (Jornvall, 
Hoog 1995, Hoog et al. 2001). 
 
The reversible reaction catalysed by ADH uses NAD/NADH as an electron 
acceptor / donor. The reaction is limited generally by maximum capacity of 
ADH, but dissociation of produced NADH, product inhibition by NADH and 
acetaldehyde, and substrate inhibition by high concentrations of ethanol also 
limit the reaction (Cederbaum 2012). The physiological substrates for ADHs 
are not known, and although research has focused on oxidation of ethanol, the 
ADH reaction strongly favours reduction of acetaldehyde in vitro. Thus, in 
absence of ethanol ADH serves to reduce acetaldehyde concentrations (Deetz 
et al. 1984). The genetic polymorphism in ADH1B discussed previously not 
only affects the rate of ethanol oxidation to acetaldehyde, but also the rate of 
acetaldehyde reduction to ethanol in vitro by hepatic ADH1B (Yin et al. 1984). 
 
The Km for hepatic ADH lies around 0.2mM, and ADH is the principal path 
for ethanol metabolism in humans (Dam et al. 2009). Different expression 
patterns of ADH isoenzymes in upper and lower digestive tract may regulate 
exposure to ethanol metabolites, with high Km ADH4 being predominant in 
the upper aerodigestive tract. Mucosal ADH activity contributes little to 
overall ethanol turnover, but probably plays a part in regulation of local 
ethanol and acetaldehyde exposure (Yin et al. 1997). 
Microsomal ethanol oxidizing system 
The microsomal ethanol oxidizing system (MEOS), comprises ethanol 
oxidation mainly by CYP2E1 (Lieber 1988). CYP2E1 has a Km of 10 mM for 
ethanol, and thus becomes of significance at higher concentrations of ethanol. 
It is inducible 4-10-fold by chronic ethanol intake (Dinis-Oliveira 2016), but 
there is however no compelling evidence for a significant contribution of 
MEOS in ethanol metabolism in vivo in humans (Dam et al. 2009).  The 
reaction is dependent on NADP and oxygen, and the end products are 
acetaldehyde, NADPH and water (Dinis-Oliveira 2016). CYP2E1 is also 
expressed in oral, (Vondracek et al. 2001) oesophageal (Millonig et al. 2011) 
and gastric mucosa (Kato et al. 2011), although the contribution to local 




Peroxisomal catalase can also oxidize ethanol to acetaldehyde in a reaction 
which requires Hydrogen peroxide (H2O2) and produces water. The 
contribution to total ethanol elimination is regarded as insignificant, due to 
low rates of H2O2 regeneration (Thurman, Handler 1989, Dinis-Oliveira 2016).  
Aldehyde dehydrogenase 
Acetaldehyde is metabolized to acetate primarily by cytosolic ALDH1B and 
mitochondrial ALDH2 in a NAD-dependent irreversible reaction. They are 
expressed in various tissues, with the highest occurrence in liver. (Yoshida et 
al. 1998). Hepatic ALDH2 is highly active, and only minute amounts, if any 
acetaldehyde can normally be detected in blood circulation after ethanol 
ingestion (< 2-5µM, mean peak acetaldehyde) (Nuutinen et al. 1984, Eriksson, 
Fukunaga 1993, Peng, Yin 2009). However, in ALDH2 deficient individuals 
with heterozygotic ALDH2*1/*2 readily measurable amounts have been 







As previously discussed, ethanol is mainly metabolized by the liver, but 
extrahepatic ethanol metabolism plays a part in regulation of local ethanol and 
acetaldehyde exposure. Measurements of ADH and ALDH activity in vitro in 
surgical tissue samples from various regions of the digestive tract show that in 
general, ADH-activity is higher than ALDH-activity, expect in pancreas. The 
ratio of ADH to ALDH activity was 1,8 in stomach, 2,7 in liver, 20,2 in 
oesophagus. ALDH-activity in tongue and gingiva were too low to be reliably 
determined (Yin et al. 1993, Dong et al. 1996, Yao et al. 1997). The active class 
I or II ALDHs are not expressed in gingiva or tongue, whereas ADH4 is (Dong 
et al. 1996, Yin et al. 1997). Thus, the ability of said tissues to oxidize 
acetaldehyde is limited, and acetaldehyde accumulates in saliva after alcohol 
intake (Homann et al. 1997). Local acetaldehyde exposure comes both from 
“instant” metabolism from the ethanol in a sip of  an alcoholic beverage, and 
“long-term” metabolism from ethanol delivered through the systemic 
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Microbial ethanol metabolism 
Microbes belonging to normal flora in the GI-tract can produce ethanol by 
anaerobic fermentation through reduction of acetaldehyde by bacterial ADH 
(Salaspuro, V. et al. 1999). In aerobic conditions, and presence of ethanol, the 
reaction can flow in the opposite direction, and ethanol is oxidized to form 
acetaldehyde (Salaspuro, M. 1997). This has been observed in humans in 
colonic contents in vitro (Tillonen et al. 1998), saliva in vivo (Homann et al. 
1997), saliva in vitro (Homann et al. 2000), achlorhydric stomach in vivo 
(Vakevainen, Tillonen, Salaspuro et al. 2000, Vakevainen et al. 2002) and in 
vitro (Vakevainen, Tillonen, Blom et al. 2001). 
 
Mouthwashings from patients with oral, pharyngeal or laryngeal cancers 
when compared to healthy controls, produced more acetaldehyde from 
incubation with ethanol in vitro, indicating that differences in microbial 
capacity of acetaldehyde production could affect head and neck cancer risk 
(Jokelainen, Heikkonen et al. 1996). The capability to produce (Jokelainen, 
Siitonen et al. 1996, Nosova et al. 1998, Vakevainen, Tillonen, Blom et al. 
2001) and metabolize (Nosova et al. 1996) acetaldehyde varies considerably 
between different strains of GI-tract microbes. In 4 out of 5 colonic aerobic 
bacteria the ADH-activity was higher than ALDH-activity by an order of 
magnitude (Nosova et al. 1998). In bacterial isolates from gastric juice made 
achlorhydric by treatment with lansoprazole species of Neisseria and Rothia, 
and Streptococcus salivarius were effective acetaldehyde producers, whereas 
Stomatococci, Staphylococci and other Streptococci produced less 
acetaldehyde. ADH activity and acetaldehyde production correlated positively 
among the strains (Vakevainen, Tillonen, Blom et al. 2001). Oral streptococci 
and yeast are able to produce significant concentrations of acetaldehyde from 
ethanol in vitro (Kurkivuori et al. 2006, Nieminen et al. 2009). Several strains 
of oral streptococci lack ALDH activity altogether, allowing for accumulation 
of acetaldehyde, although some strains are able to produce acetate from 
ethanol, indicating ALDH activity (Pavlova et al. 2013). In a study with 65 
volunteers, acetaldehyde concentration in mouth air correlated positively and 
statistically significantly with the amount of tongue coating, but not with other 
clinical parameters such as presence of Candida species, smoking, ALDH2 
genotype, or alcohol drinking frequency. The authors suggest that tongue 
coating acts as a reservoir for acetaldehyde producing microbes. Mechanic 
removal of tongue coating significantly decreased acetaldehyde 
concentrations in mouth air (Yokoi et al. 2015). Reduction of acetaldehyde 
concentration in saliva incubated with alcoholic beverages in vitro has been 
demonstrated using killed Gluconobacter kondonii cells, which possess 
acetaldehyde decomposing properties even in the presence of ethanol 
(Yamaguchi et al. 2012). This opens up a line of research using microbes in 
reduction of acetaldehyde exposure. Studies on salivary microbiome 




Candida Albicans has been shown to produce acetaldehyde from ethanol 
and glucose when incubated in vitro (Tillonen et al. 1999b, Uittamo et al. 
2009, Gainza-Cirauqui et al. 2013, Marttila, Uittamo et al. 2013, Marttila, 
Bowyer et al. 2013). Strains isolated from smokers produced higher 
concentrations of acetaldehyde, whereas alcohol drinking, current oral 
squamous cell cancer or oral lichenoid disease had no such effect (Marttila, 
Uittamo et al. 2013). In one study Candida albicans isolates from patients with 
precancerous oral lesions produced less acetaldehyde from ethanol than 
strains from healthy controls (Gainza-Cirauqui et al. 2013). Candida yeasts 
have been implicated in the appearance of oral and oesophageal carcinoma, 
and in a study comparing Candida species from patients with oral cancer vs. 
controls a significant positive association between oral cancer and Candida 
virulence factors, such as ability to form microfilms, and production of 
hydrolytic enzymes and ability to metabolize ethanol to acetaldehyde was 
found (Alnuaimi et al. 2016). 
 
The ability of a microbial isolate to produce acetaldehyde in vitro does not 
necessarily correlate with the acetaldehyde production ability when present in 
the oral microbiome. This was shown with Neisseria species, which when 
isolated are potent acetaldehyde producers, but salivary samples showed an 
inverse correlation with the relative abundance of Neisseria and acetaldehyde 
production capability of saliva incubated with ethanol in vitro (Yokoyama, S. 
et al. 2018). 
 
In piglets receiving intracolonically administered acetaldehyde, the 
acetaldehyde was effectively metabolized, as shown by increasing intracolonic 
acetate and ethanol concentrations (Jokelainen, Matysiak-Budnik et al. 1996). 
Acetaldehyde is also readily absorbed into the portal blood in rats receiving 
acetaldehyde into either the colon or stomach. Some of the intracolonically 
administered acetaldehyde was metabolized to ethanol, and detected in portal 
venous blood, whereas intragastrically administered was not. It was concluded 
that acetaldehyde was probably metabolized to ethanol by colonic microbial 
ADH (Matysiak-Budnik et al. 1996). 
 
Antibiotic treatment with ciprofloxacin was shown to reduce ethanol 
elimination rate in humans by 9.4% in vivo, while concurrently reducing faecal 
acetaldehyde production, and faecal ADH-activity in vitro (Tillonen et al. 
1999a). Metronidazole treatment increased intracolonic acetaldehyde 
concentrations in rats, probably due to replacement of intestinal anaerobes 
with ADH containing anaerobes (Tillonen et al. 2000). Lactulose reduces 
ethanol elimination rate, and colonic acetaldehyde concentration in rats after 
ethanol administration (Zidi et al. 2003). These findings point to a significant 
contribution of the gastrointestinal microbiome to overall ethanol elimination, 
and regulation of acetaldehyde concentration in the GI-tract. 
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Alcohol consumption is carcinogenic in humans (IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans 2010). Evidence points to that 
acetaldehyde is predominantly responsible for carcinogenesis associated with 
alcohol consumption. Ethanol in itself as a molecule is not capable of 
producing the necessary mutations required for emergence of cancer (Poschl, 
Seitz 2004), and there is no significant evidence that ethanol itself is genotoxic 
(Phillips, Jenkinson 2001). Possible mechanisms for carcinogenesis related to 
ethanol consumption are summarised below. 
 
Ethanol consumption induces hepatic cytochrome P450 2E1 activity, 
leading to increased reactive oxygen species, lipid peroxidation and generation 
of lipid peroxidation products, such as 4-hydroxynonenal which binds to DNA 
forming carcinogenic exocyclic DNA-adducts. CYP2E1 is also involved in 
activation of various xenobiotics and procarcinogens, such as aflatoxin. 
Furthermore, CYP2E1 metabolizes retinol and retinoic acid resulting in 
cellular hyperregeneration (Seitz, Mueller 2015). Ethanol influences DNA 
methylation and induces histone modification associated with altered 
expression of several genes, including oncogenes (Shukla, S. D., Lim 2013). 
Alcohol may increase permeability of carcinogens into mucosa (Wight, Ogden 
1998), increase inflammation, which may promote tumorigenesis (Shukla, P. 
K. et al. 2016), and decreased immune response which could be associated 
with cancer progression (Zhang, H., Meadows 2010). 
Acetaldehyde 
Exposure to acetaldehyde vapor for 52 weeks has been shown to produce 
laryngeal carcinomas in Syrian golden hamsters (Feron et al. 1982). 
Furthermore, acetaldehyde exposure by inhalation for up to 28 months caused 
an increased incidence of carcinomas in nasal mucosa and olfactory 
epithelium of rats (Woutersen et al. 1986). Acetaldehyde administered in 
drinking water to rats caused a slight overall increase in malignant tumours 
(Soffritti et al. 2002). IARC concluded in 1999 that there is sufficient evidence 
supporting the carcinogenicity of acetaldehyde in animals, but inadequate 
evidence in humans (IARC 1999). Largely due to epidemiologic evidence from 
ALDH2-deficient individuals with increased risk for UADT cancers with 
alcohol consumption, “acetaldehyde associated with the consumption of 
alcoholic beverages” was classified as carcinogenic in humans in 2009 (IARC 




Unlike ethanol, acetaldehyde probably acts as a direct chemical carcinogen 
by forming adducts with DNA, which can lead to DNA mutations and 
consequently cancer. It can also induce sister chromatid exchanges and gross 
chromosomal aberrations. It can cause structural and functional changes in 
cellular proteins by binding to them, such as enzymes involved in DNA repair 
and DNA methylation. (Brooks, Zakhari 2014, Seitz, Stickel 2007). Increased 
levels of the major acetaldehyde-DNA-adduct N2-ethylidenedeoxyguanosine 
can be found in oral mucosal cells after alcohol ingestion, at a level up to 100-
fold compared to baseline, and in a dose-responsive manner at 0.3‰, 0.5‰, 
and 0.7‰ BAC. (Balbo et al. 2012). In this study a similar alcohol 
administration protocol was used as in these studies on salivary acetaldehyde 
after ethanol administration, where the target BAC was 0.5‰ (Homann et al. 
1997, Linderborg et al. 2011). In the study by Balbo et. al. vodka was diluted by 
an unspecified amount before administration, unlike in our study where vodka 
and calvados were sipped neat. However, combining data from these studies 
makes it is plausible that acetaldehyde reacts with DNA in salivary 
acetaldehyde concentrations around 100µM. 
 
Increased levels of N2-ethylidenedeoxyguanosine adducts have been 
observed in ALDH2-deficient alcohol fed mice liver and stomach, when 
compared to mice with normal ALDH2 activity (Matsuda et al. 2007, 
Nagayoshi et al. 2009). Increased amounts of N2-ethylidenedeoxyguanosine 
adducts were also observed in white blood cells of alcoholics (Fang, J. L., Vaca 
1997). In ALDH2-deficient alcoholics compared with alcoholics with normal 
ALDH2-activity the levels of three acetaldehyde-derived adducts where 
significantly elevated (N2-ethylidenedeoxyguanosine, α-S-, and α-R-methyl-γ-
hydroxy-1,N2-propano-2′-deoxyguanosine) (Matsuda et al. 2006). 
Furthermore, acetaldehyde adducts have been demonstrated in oral tissues of 
alcohol  consuming patients with squamous cell cancer and pre-cancerous oral 
lesions (Warnakulasuriya et al. 2008). These adducts seem to be a promising 
marker for acetaldehyde exposure at the DNA-level. 
 
Acetaldehyde has also been shown to cause telomere shortening in various 
human cell lines. Telomere shortening was observed during exposure to 
moderate amounts of ethanol (25mM), and acetaldehyde (25µM). Both 
concentrations are relevant in the upper digestive tract in a social drinking 
setting. Furthermore, this telomere shortening during ethanol exposure was 
inhibited by the alchohol dehydrogenase inhibitor 4-methylpyrazole (Harpaz 
et al. 2018). 
 
Acetaldehyde has been found to be able to form mutagenic Cr-PdG adducts 
in vitro in the presence of an abundance of spermidine at acetaldehyde 
concentrations of 100µM and above (Theruvathu et al. 2005). It can inhibit 
O6-methylguanine transferase, a DNA-repair enzyme, at concentrations as low 
as 0.01µM (Espina et al. 1988). It is however unknown how these in vitro 
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findings translate to in vivo situations, and thus any estimates on what level 
of acetaldehyde concentrations are required for carcinogenesis in humans, 
and whether there is any safe lower limit for acetaldehyde exposure, are 
tenuous at best (Balbo, Brooks 2015). 
Human ALDH2 ”knock-out model” for acetaldehyde exposure in the 
upper gastrointestinal tract. 
Combining epidemiological and biochemical studies focusing on the point 
mutation in the ALDH2 gene provides evidence proving the association 
between local acetaldehyde exposure, and upper digestive tract cancer 
(Lachenmeier, Salaspuro 2017, Nieminen, Salaspuro 2018). The two main 
findings leading to this conclusion are that ALDH2-deficient individuals have 
approximately twice as much acetaldehyde in their saliva after a dose of 
alcohol when compared to ALDH2-actives. The acetaldehyde exposure 
endures for as long as there is alcohol present in the body (Vakevainen, 
Tillonen, Agarwal et al. 2000, Vakevainen, Tillonen, and Salaspuro 2001, 
Yokoyama, A. et al. 2008, Maejima et al. 2015, Yokoyama, A. et al. 2016). 
Secondly, alcohol consumption combined with ALDH2-deficiency associates 
with a significantly increased risk for upper gastrointestinal tract cancer 
(Yokoyama, A. et al. 1996, Nomura et al. 2000, Lewis, Smith 2005, Boccia et 
al. 2009, Matsuo et al. 2013). 
 
The benefit of this model is that nature has randomized millions of 
individuals to different amounts of acetaldehyde exposure, and this also allows 
for minimizing the effect of confounding factors such as  smoking, diet, oral 
hygiene, HPV, different beverages, drinking habits and BMI (Lachenmeier, 
Salaspuro 2017). 
 
This model, although comprised of a combination of data from several 
studies, has allowed for the estimation of the amount of increased 
acetaldehyde exposure needed to cause an increased risk for UADT cancer. By 
multiplying salivation rate by salivary acetaldehyde concentration during 
drinking and duration of acetaldehyde exposure Lachenmeier and Salaspuro 
calculated that in ALDH2 deficients drinking heavily (7 drinks, 77g/day) an 
increased acetaldehyde exposure of 6.7 µg/kg bw/ day is achieved. This level 
of alcohol consumption is associated in ALDH2 deficients with a OR of 7.28 
for head and neck cancer, and 7.12 for oesophageal cancer (Lachenmeier, 
Salaspuro 2017). This amount of acetaldehyde in a person weighing 80kg 
amounts to 536 µg / day or 12 µmol / day. A seemingly low amount. In 
comparison, according to our data a single shot (4 cl) of calvados (1780 µmol/l) 
contains 71 µmol of acetaldehyde (Linderborg et al. 2008). The problem with 
this model is that it is based on the flow of saliva, and acetaldehyde 
concentration in it, and attempts to calculate a total dose of acetaldehyde, 
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when in truth acetaldehyde is produced continuously. This issue is addressed 
in another model as described below. 
 
Nieminen and Salaspuro proposed another model for estimating increased 
acetaldehyde exposure in ALDH2 deficients, and combining it to 
epidemiological data on cancer risk. In this model the average increased 
acetaldehyde concentration in ALDH2 deficients is multiplied by the 
estimated time of exposure / day in order to receive an area under the curve of 
exposure time multiplied by concentration. Exposure to salivary acetaldehyde 
from cigarette smoking is also calculated, and the AUC:s for calculated 
exposures of each source for acetaldehyde correspond nicely to odds ratios for 
oropharyngeal cancers obtained from epidemiological data (Nieminen, 
Salaspuro 2018). The model is useful when comparing exposure to 
acetaldehyde, when salivary acetaldehyde concentration is known, and 
correlating it to risk data from epidemiological studies. However, the paper 
also suggests extrapolation to yoghurts and fruits with high acetaldehyde 
concentration, but low or no ethanol concentration. These extrapolations 
should be considered carefully, as there is currently no data on salivary 
concentration of acetaldehyde after ingestion of foodstuffs or beverages 
containing acetaldehyde without ethanol. Yoghurt and fruits usually contains 
substantial amounts of acetaldehyde (Uebelacker, Lachenmeier 2011), yet 
consumption of yoghurt was associated with a decreased risk of UADT cancer 
in a Japanese case-control study of  959 patients with UADT cancer and 2877 
controls (Kawakita et al. 2012). 
 
The importance of acetaldehyde and ALDH2-activity in carcinogenesis was 
further underlined in a study on mice, and cultured human oesophageal 
keratinocytes. It was shown that alcohol drinking in mice in vivo, and 
acetaldehyde exposure in cell cultures promoted ALDH2 expression. 
Furthermore, N2-ethylidenedeoxyguanosine concentration in mouse and 
human keratinocytes, representing acetaldehyde-derived DNA damage was 
higher in ALDH2 knockout-mice than in controls, and further increased by 
treatment with acetaldehyde. Finally, forced ALDH2-production decreased 
N2-ethylidenedeoxyguanosine levels. This evidence adds to the importance of 
ALDH2 in oesophageal tissue in protection against DNA damage caused by 
acetaldehyde (Amanuma et al. 2015).  
Acetaldehyde exposure 
From ethanol metabolism 
There is 11.71 grams of ethanol in a typical bottle of beer (0.33l, 4.5 vol%) This 
ethanol, when metabolized produces 11.25g of acetaldehyde. The bulk of this 
metabolism takes place in the liver, where acetaldehyde is immediately 
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oxidized to acetic acid by hepatic ALDH enzymes (Nuutinen et al. 1984). The 
elimination of acetaldehyde in the oral cavity is far from as effective as in liver, 
and microbial metabolism of ethanol leads to accumulation of marked 
amounts of acetaldehyde in saliva after ingestion of moderate amounts of 
ethanol (Homann et al. 1997). Poor dental status leads to increased 
acetaldehyde production from ethanol in saliva (Homann et al. 2001). 
Acetaldehyde exposure is further increased by acetaldehyde formed instantly 
after a sip of an alcoholic beverage (Linderborg et al. 2011). Significant 
concentrations of acetaldehyde were also found in saliva immediately after 
using alcohol containing mouthwashes (Lachenmeier, Gumbel-Mako et al. 
2009, Moazzez et al. 2011). 
 
Ethanol is not only found in alcoholic beverages, but also in varying 
amounts in foods. Ethanol can stem from adding an alcoholic beverage during 
preparation, or from fermentation of the food, or an ingredient thereof. In a 
German survey the researchers found ethanol concentrations up to 2.6 g/L in 
vinegar, 2.15 g/L in malt beer, and 0.86 g/L in grape juice. Some types of bread 
also contained up to 1.28 g / 100g ethanol, while on average breads contained 
0.22g / 100g ethanol. The amounts are relatively small when compared to 
ethanol in alcoholic beverages (Gorgus et al. 2016). The amount of ethanol 
remaining in a dish after an alcoholic beverage is added during preparation 
depends mostly on for how long the dish is being cooked, and how freely 
ethanol is allowed to evaporate. The amount of ethanol in a single serving of 
food is however approximately only a tenth to a fifth of the amount of ethanol 
in a single serving of an alcoholic beverage (Augustin et al. 1992). Whether 
ethanol in food contributes to acetaldehyde exposure and cancer risk is 
unknown. As discussed previously, there is no safe lower limit of alcohol 
consumption in relation to overall cancer risk. Even light drinking is a risk 
factor for oropharyngeal and oesophageal cancer (Bagnardi et al. 2013), 
whereas light drinking does not seem to increase the risk of pharyngeal or 
gastric cancer. There is clear evidence of dose dependency with regard to 
alcohol consumption and upper digestive tract cancer, and thus it seems 
unlikely that the small amounts of alcohol in foods contributes significantly to 
cancer risk, but this is something that has yet to be investigated. It can be 
expected that acetaldehyde related carcinogenicity from foods produced by 
fermentation that contain some alcohol (0-5%) is of the same order of 
magnitude as from light drinking. There might exist an epidemiological bias, 
due to that there is no systematic data on the use of foods with ethanol or 
acetaldehyde content and upper digestive tract cancer risk. Nor is there 
systematic information available on acetaldehyde content in foods. 
Outside ethanol metabolism 
Acetaldehyde is formed in small amounts through enzymatic breakdown of 
threonine, by threonine aldolase (Lin, Greenberg 1954). A small amount of 
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acetaldehyde can be produced by bacterial metabolism without ethanol 
drinking, but not in measurable amounts in blood or saliva (Vakevainen, 
Tillonen, Agarwal et al. 2000, Vakevainen, Tillonen, and Salaspuro 2001, 
Yokoyama, A. et al. 2008). The bulk of acetaldehyde exposure is through 
alcohol drinking by metabolism of ethanol to acetaldehyde. 
 
Acetaldehyde can also be found in varying amounts in different alcoholic 
beverages (Lachenmeier, Sohnius 2008, Boffetta et al. 2011, Paiano et al. 
2014) and in some foodstuffs, especially fruits and yoghurts (Uebelacker, 
Lachenmeier 2011, Miyake, Shibamoto 1993). Acetaldehyde is a fruit 
metabolite, and a natural aroma component, that accumulates during fruit 
ripening (Pesis 2005). Because of its aromatic properties, and insufficient data 
on carcinogenicity until recent times it is still used widely as a food additive 
(Feron et al. 1991).  
 
Tobacco smoke contains acetaldehyde among other toxic constituents, and 
it is readily absorbed readily in the mouths of smokers (Dalhamn et al. 1968). 
Salivary acetaldehyde concentration increased rapidly from zero to 261µM 
during smoking a single cigarette, and decreased to baseline in no more than 
5 minutes after cessation of smoking (Salaspuro, V., Salaspuro 2004). 
Smoking also seems to alter acetaldehyde metabolism in the mouth and saliva. 
Smokers had approximately twofold salivary acetaldehyde concentrations 
after ethanol ingestion without concurrent cigarette smoking compared to 
non-smokers. Acetaldehyde production in saliva from ethanol in vitro was also 
higher in smokers vs. non-smokers (Homann et al. 2000). 
 
Acetaldehyde exposure from foods has been estimated to be from 3mg to 
200mg / day for a person weighing 75kg (Uebelacker, Lachenmeier 2011). No 
studies have so far been undertaken to determine how this acetaldehyde 
contributes to mucosal acetaldehyde exposure. 
 
Acetaldehyde in alcoholic beverages is primarily formed from sugar as a by-
product of alcoholic fermentation by yeasts. The rate of acetaldehyde 
production during fermentation is influenced by a multitude of factors, 
including species of yeast, temperature, presence of oxygen, and sulphur 
dioxide concentration. Sulphites are also used as additives in winemaking for 
their antimicrobial, antioxidative and acetaldehyde binding properties. 
Sulphites have a strong affinity for binding to acetaldehyde, reducing 
concentrations of free acetaldehyde in wines (Liu, Pilone 2000). In distilled 
alcoholic beverages the acetaldehyde concentration depends largely on the 
method of distillation, but also maturation of beverages (Nykänen, 
Suomalainen 1983, pp. 52-53). 
 
Acetaldehyde concentrations in saliva after drinking different alcoholic 
beverages with different concentrations of acetaldehyde have been studied by 
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Yokoyama et. al.  and Lachenmeier et. al. Yokoyama measured salivary 
acetaldehyde immediately after drinking, and at 30-minute intervals, and no 
difference in salivary acetaldehyde concentration was observed apart from the 
first sample, where acetaldehyde concentrations were significantly higher 
after drinking diluted calvados or shochu, containing 600µM acetaldehyde, 
compared to wine containing 250µM acetaldehyde. The acetaldehyde 
concentration in beverage had no effect on blood acetaldehyde concentration 
(Yokoyama, A. et al. 2008). In the study by Lachenmeier no simultaneous 
alcohol ingestion was studied. The results were in line with previous data. They 
found that acetaldehyde in beverages affect the salivary acetaldehyde 
concentration for less than two minutes after tasting a beverage for 30 seconds 
(Lachenmeier, Monakhova 2011). 
 
Cysteine and acetaldehyde 
The semi-essential amino acid L-cysteine condenses readily in a 
nonenzymatic, reversible reaction with acetaldehyde in physiological 
conditions forming 2-methyl-4-thiazolidine-carboxylic acid (MTCA) (Reischl 
et al. 2012). Thus, it could potentially be used as harm reduction by reducing 
exposure to acetaldehyde. L-cysteine has been shown to bind acetaldehyde 
derived from tobacco smoke in vitro (Braven et al. 1967), and in saliva in vivo 
(Salaspuro, V. J. et al. 2006), and decrease acetaldehyde concentration in 
saliva after alcohol drinking (Salaspuro, V. et al. 2002). A buccal tablet 
releasing cysteine and chlorhexidine was also effective in reducing 
acetaldehyde concentration in saliva after ethanol exposure in vivo (Juliano et 
al. 2011). The safety of cysteine supplementation is examined next. 
Safety of cysteine 
L-Cysteine is an endogenous excitotoxin that can damage the central nervous 
system in experimental animals with immature central nervous systems before 
the development of an intact blood-brain barrier (Olney et al. 1990). An excess 
cysteine supplementation of 7.5 times the dietary requirement was lethal in 
chicks after 5 days of treatment, the cause of death being severe metabolic 
acidosis. An excess cysteine supplementation in food decreased weight gain in 
pigs (Dilger et al. 2007, Dilger, Baker 2008). 
 
Evidence for toxicity in humans is however scarce. Kartal-Hodzic et. al. 
examined the toxicity and permeability of cysteine and MTCA on Caco-2 cells 
and found no evidence of harm to these cell cultures at concentrations up to 
1200 µg/ml for L-cysteine and 600 µg/ml for MTCA (Kartal-Hodzic et al. 
2013). Ingestion of a single dose of 5g and 10g of cysteine produced nausea 
and light-headedness in healthy subjects (Carlson et al. 1989). The liver is an 
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effective regulator of cysteine. By synthesizing glutathione, which serves as a 
cysteine reservoir it keeps cysteine levels appropriate, allowing for normal 
metabolism, but keeping cysteine levels below the threshold for toxicity 
(Stipanuk et al. 2006). 
 
Cysteine is found in proteins in normal diet, and it is also taken as dietary 
supplements. It is used as an additive in flour to improve baking properties. 
Daily intake requirements in humans according to WHO for sulphur 
containing amino acids cysteine and methionine combined is 13mg/kg body 
weight (Energy and protein requirements report of a Joint FAO/WHO/UNU 
Expert Consultation. 1985). The mean daily intake of cysteine according to 
data from a survey in Americans was 1g/day in all age groups, whereas the 
highest intake of 2.2g/day was found at the 99th percentile of men at 51-70 
years of age. It has been concluded that there is insufficient data to establish a 
safe upper limit for cysteine intake from supplements (Panel on 
Macronutrients et al. 2005). Some research points to a need for cysteine 
supplementation, and positive effects thereof, in elderly people (Droge 2005, 
Nimni et al. 2007). 
 
Safety of MTCA 
What happens to MTCA in the digestive tract is largely unknown, as are the 
potential effects of MTCA on humans in general as the subject is insufficiently 
studied. MTCA can break down spontaneously into cysteine and acetaldehyde. 
Radioactively labelled 14C-MTCA, fabricated from cysteine and 14C-
acetaldehyde, was given to rats intraperitoneally. 52.8% of the radioactive dose 
was expired as 14CO2 within the first 4 hours, indicating rapid dissociation of 
acetaldehyde and subsequent metabolism (Nagasawa et al. 1982). In a similar 
experiment 13.6% of the radioactivity was recovered in urine within 4 days, 
also suggesting active metabolism of MTCA. The finding was limited by the 
fact that faecal excretion of MTCA was not assessed (Kallama, Hemminki 
1983). 
 
MTCA can be freely nitrosated in a nonenzymatic reaction to NMTCA in 
presence of nitrite, optimally in acidic conditions (pH4.5). Thus, NMTCA can 
form spontaneously from acetaldehyde, cysteine and nitrite. NMTCA when 
given orally to rats, is recovered up to 95% in urine and faeces within 2 days 
from administration (Ohshima et al. 1984). NMTCA can be detected in human 
urine, albeit in very small amounts of 0.4 -27.6 µg / 24h. The urine of cigarette 
smokers contained twice as much NMTCA as non-smokers, possibly due to 
endogenously derived NMTCA from acetaldehyde in cigarette smoke (Tsuda 
et al. 1987). 
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MTCA can be detected in human blood after consumption of ethanol, 
suggesting that it is endogenously formed from cysteine and acetaldehyde, 
inactivating endogenous or exogenous acetaldehyde. Peak blood MTCA 
concentration was 12.6mg/L (85µM) 4 hours after an ethanol intake of 0,5g 
/kg bw (Reischl et al. 2012). 
 
In conclusion, there is evidence that cysteine can be used to reduce 
acetaldehyde concentrations in saliva.  The safety of cysteine supplementation 
is however not known, and a safe upper limit for cysteine supplementation has 
not been established. 
Atrophic gastritis and gastric achlorhydria 
Helicobacter pylori infection is a significant risk factor for developing chronic 
atrophic achlorhydric gastritis and subsequent development of gastric cancer 
(Kuipers et al. 1995, Correa et al. 1990). The risk ratio for gastric cancer in 
people chronically infected with H. Pylori seems to be around 2-3-fold 
(Danesh 1999).  Severe atrophic gastritis has been known to be a risk factor for 
gastric cancer for over 30 years (Sipponen et al. 1985). In a large Finnish study 
H. pylori infection was associated with a 5.8-fold risk for stomach cancer (95% 
CI 2.7-15.3), and serologically confirmed atrophic gastritis was associated with 
a 9.1-fold risk for stomach cancer (95% CI 2.9-30) (Vohlonen et al. 2016). 
Pernicious anaemia has also been linked with an approximately threefold risk 
of stomach cancer in epidemiologic studies. Again, this is probably through 
the underlying atrophic gastritis, and achlorhydria (Brinton et al. 1989). In a 
Japanese case-control study with 45 cases of gastric carcinoma ALDH2 
deficiency, and chronic atrophic gastritis were independent risk factors for 
gastric cancer, and the combination of severe chronic atrophic gastritis and 
ALDH2 deficiency resulted in a 39-fold risk for development of gastric cancer 
(OR=39.2, 95%CI 6.4-239) (Yokoyama, A. et al. 2007). 
 
Interestingly also the risk for oesophageal squamous cell carcinoma 
(ESCC), but not adenocarcinoma was increased threefold in atrophic gastritis 
related to pernicious anaemia (Ye, Nyren 2003). In another Japanese case-
control study with 63 cases of ESCC, the investigators examined the 
association of hypochlorhydria, and ALDH2-deficiency with ESCC and found 
an increased risk for ESCC in hypochlorhydria alone (OR=4.4, 95%CI 1.3-
15.0). No increased risk was observed in ALDH2 deficiency alone (OR=1.6, 
95% CI 0.5-5.2), whereas the combination of inactive ALDH2 and 
hypochlorhydria resulted in a markedly increased risk for ESCC (OR=21.8, 
95%CI 4.9-97.0) (Oikawa et al. 2010).  
 
Atrophic gastritis leads to increased bacterial growth in the stomach 
through achlorhydria. At gastric pH less than 4.0 99.9% of bacteria are killed 
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in less than 30 minutes (Giannella et al. 1972). This gastric acid barrier is 
effective against most bacteria with the exception of Helicobacter Pylori and 
some acid resistant lactobacilli (Marshall et al. 1990, Aiba et al. 2015). In 
achlorhydria the stomach is colonized with a large number of bacteria (Drasar 
et al. 1969). Gastric bacterial counts are also increased by acid suppressive 
drugs such as omeprazole(Verdu et al. 1994), and cimetidine (Ruddell et al. 
1980). 
 
Helicobacter pylori also possesses ADH activity, and is able to produce 
significant concentrations of acetaldehyde when incubated in clinically 
relevant ethanol concentrations in vitro (Roine et al. 1992). 
 
In healthy volunteers who served as their own controls, Lansoprazole 30mg 
twice a day for 7 days resulted in decreased pH of gastric juice, increased 
bacterial count in gastric juice, and in an increased gastric juice acetaldehyde 
concentration (mean ± SEM 55.4 ± 8.0 µM vs. 22.1 ± 2.3 µM) after ethanol 
ingestion of 0.6g/kg body weight (Vakevainen, Tillonen, Salaspuro et al. 
2000). Similar results were obtained when comparing volunteers with 
atrophic gastritis to healthy volunteers. Gastric juice acetaldehyde 
concentrations were (mean ± SEM) 44.5 ± 9.2 µM vs 9.8 ± 0.9 µM at 30 
minutes after instillation of ethanol 0.3g/kg bw via nasogastric tube 
(Vakevainen et al. 2002). 
 
In conclusion, achlorhydria results in increased gastric juice acetaldehyde 
concentration after ethanol ingestion. ALDH2-deficient healthy volunteers 
had approximately 5 times higher peak gastric juice acetaldehyde 
concentrations after intragastric ethanol infusion, when compared to ALDH2-
proficient peers (Maejima et al. 2015). An increased acetaldehyde exposure 
could explain the increased risk for gastric cancer in ALDH2-deficient 
individuals with severe chronic atrophic gastritis, as discussed above in this 
chapter. 
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AIMS OF THE STUDY 
Acetaldehyde associated with consumption of alcoholic beverages is 
carcinogenic in humans. The bulk of acetaldehyde exposure comes from 
ethanol metabolism but acetaldehyde in alcoholic beverages might also have 
significance, especially regarding different risks of upper aerodigestive tract 
cancers associated with consumption of different beverages, in this case 
calvados. 
 
Furthermore, a feasibility study on reducing exposure to acetaldehyde in 
achlorhydric stomach with L-cysteine was conducted. 
 
Specific aims were as follows: 
 
I. To investigate acetaldehyde concentrations in calvados from 
industrial and rural sources and compare them to other alcoholic 
beverages. The findings could elucidate the role of acetaldehyde 
found in alcoholic beverages in the increased risk for oesophageal 
cancer connected to consumption of calvados. 
II. To examine acetaldehyde concentrations in saliva after single sips of 
strong alcoholic beverages containing either no acetaldehyde or high 
concentrations of acetaldehyde, and thus compare the resultant 
exposure to acetaldehyde from these beverages, and to explore the 
significance of acetaldehyde in beverages to overall acetaldehyde 
exposure in the mouth. 
III. To determine if L-cysteine can be used to bind acetaldehyde 
produced in the achlorhydric stomach from ingested ethanol and 
reduce the exposure to acetaldehyde. 
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MATERIALS AND METHODS 
Potential mechanism for calvados-related oesophageal 
cancer 
Samples 
Eighteen samples of farm-made calvados were collected in the Manche, Orne, 
Eure and Seine-inferieure areas in Normandy in 2001-2002. Two samples of 
farm-made cognac were obtained in Gironde of southwestern France. The 
samples were collected with disposable syringes and needles and stored in 
vacutainer tubes at 6°C until analysis. Samples of commercially available 
beverages were purchased from Alko Inc, and samples were extracted just 
prior to analysis from previously unopened bottles. These included seven 
different factory-made calvadoses, four cognacs, two scotch blended whiskies, 
two rums, one pear-cognac liqueur, one vodka, three white wines, three red 
wines, three beers and three ciders. These were grouped as 25 calvadoses, 12 
other spirits, 6 wines and 6 beers and ciders. Every commercially available 
calvados from Alko was obtained, whereas other beverages were selected by 
availability in miniature bottles. 
Analysis 
Samples were diluted for analysis, based on estimated ethanol concentration, 
in purified water. Spirits were diluted 1:100, wines 1:30 and beer and cider 
1:10. 500µl of the diluted sample was transferred into a glass vial, and 
subsequently analysed by headspace gas chromatography (Perkin Elmer 
Autosystem gas chromatograph, Massachusetts, USA). For acetaldehyde 
analysis, the vials were heated to 37°C. The parameters for gas 
chromatography were as follows: Column 60/80 Carbopack B/5% Carbowax 
20 M, 2m x 1/8″; oven temperature 85°C; transfer line and detector 
temperature 200°C; carrier gas flow rate (N2) 20ml/min. For ethanol analysis, 
the vials were further diluted 1:10, and the headspace vials were heated to 
65°C. Gas chromatograph parameters were as above. Statistical analysis was 
performed with SPSS 13.0.1. (SPSS Inc, Chicago, IL, USA) using one-way 
ANOVA and Tukey’s HSD. 
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A single sip of a strong alcoholic beverage causes 
exposure to carcinogenic concentrations of 
acetaldehyde in the oral cavity 
Subjects 
Eight healthy volunteers aged 26 ± 4 (years ± SD) participated in the study.  
There were 4 females, and 4 males. Mean body weight ± SD was 78 ± 18 kg. 
The volunteers were non-smokers and social drinkers consuming less than 
14/20 (female / male) doses of alcohol per week. None of the volunteers had 
received any antibiotics for 1 month preceding the study, and they were asked 
to refrain from alcohol intake for 24h prior to the study. 
Beverages 
Calvados containing 2400µM acetaldehyde or 96% ethanol diluted in water 
were used. Final ethanol concentration in each beverage was 40 vol. %. The 
ethanol beverage contained no acetaldehyde. Ethanol and acetaldehyde 
concentrations of the beverages were measured after 1:100 dilution by 
headspace gas chromatography as described above. 
Study design 
The ethics committee of the department of medicine, Helsinki University 
Central Hospital approved the study, and informed consent of the participants 
were obtained. The subjects served as their own controls. 
 
A light breakfast was allowed at least 90 minutes prior to commencement 
of the experiment. To simulate a sip of alcoholic beverage the volunteers were 
given 5ml of each beverage to taste in their mouths for 5 seconds, whereafter 
they spit several times to expunge all beverage. Samples were collected by 
spitting at 30 seconds, 2, 5 and 10 minutes. A fifteen-minute wash-out period 
was used between beverages. The order in which the beverages were tested was 
varied between participants. 
 
A test run using 40% ethanol was performed 25 minutes prior to the actual 
test in order to accustom the participants to the protocol, and to minimise the 
possible difference in subsequent measurements due to previously taken 
alcohol. 
 
To examine the effect of alcohol in the bloodstream the tests were repeated 
at a blood alcohol content of 0.4-0.5 ‰. Participants consumed 0.5g / kg body 
weight ethanol diluted in water to 10 vol%. Blood alcohol concentration was 
monitored by a breath alcohol content analyser (Dräger Alcotest 7410 Plus, 
 
37 
Lubeck, Germany) at 5-minute intervals until it was stabilized at 0.4-0.5 ‰. A 
control salivary sample was then taken, and the sampling run was repeated for 
the first beverage. Then the volunteers received an additional dose of ethanol 
(0.05g / kg body weight), whereafter the blood alcohol content was again 
monitored until stable at 0.4 – 0.5 ‰ and the sampling run was repeated for 
the other beverage. 
Acetaldehyde and ethanol analysis 
450µl of saliva was transferred into headspace vials containing 50µl of 6M 
perchloric acid. Acetaldehyde and ethanol concentrations were analysed by 
headspace gas chromatography as described in the previous section. The 
ranges of detection for acetaldehyde and ethanol were 2.5-800µM and 1-
150mM respectively. 
 
Statistical analysis was done using SPSS 15.0.1 statistical software (SPSS 
Inc., Chicago, IL, USA). Wilcoxon’s nonparametric test for paired samples was 
used to test for statistical significance. 
Reducing carcinogenic acetaldehyde exposure in the 
achlorhydric stomach with cysteine 
Preparation of cysteine and placebo capsules 
The capsules, prepared at the University Pharmacy in Helsinki, contained 50 
mg of l-cysteine as an active ingredient. Five hundred grams of l-cysteine 
(Gonmisol S.A., Barcelona, Spain), 500 g of Eudragit RS-PO forming the 
matrix structure (Evonik Rohm GmbH, Damstadt, Germany), and 1 kg of 
calcium hydrogen phosphate as an inactive additive (CaHPO4, Emcompress® 
Anhydrous; Mendell a Penwest Company, Lakeville, MN) were mixed in a 
Turbula Powder Blender (Glen Mills Inc., Clifton, NJ) for 10 minutes, and the 
mixture was wet-granulated using ethanol. The wet granules were sieved using 
a 2-mm sieve and thereafter allowed to dry at room temperature in a fume 
hood for 24 hours. The dried granules were sieved using 1.68 mm and 1.18 mm 
sieves, and the fraction between 1.68 mm and 1.18 mm was collected for 
capsulation. Simultaneously, a placebo formulation where l-cysteine was 
replaced with the same amount of CaHPO4 was prepared following exactly the 
same method. The matrix granules formed were weighed into hard gelatine 
capsules to ease the administration such that each capsule contained 
200 mg of granules, equalling 50 mg of l-cysteine. The l-cysteine 
concentration of the granules was determined using a capillary method (400 
mg of granules contained 98 mg of l-cysteine). 
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Dissolution Test for the Capsules 
Dissolution tests for the capsules were performed according to the USP I 
method (USP 24) (The United States Pharmacopeia 2001). A standard curve 
was prepared between 0.01 and 0.6 mg ⁄ ml (y = 2.196 + 0.0016, r2 = 0.9999). 
The medium used was 500 ml of pH 1.2 HCl buffer. The rotation rate of the 
baskets was 100 rpm, and the temperature of the medium was +37°C (±0.5). 
Samples were taken at 5-minute intervals for the first half hour and thereafter 
at 10-minute intervals for the remaining 2 hours. L-cysteine was detected in 
flow-through cells (10 mm) at a wavelength of 213 nm. The results were 
calculated by using dissolution software. The system was equipped with a bath 
and pump (Sotax AT7 UV Dissolution System; Sotax, Allschwil, Switzerland) 
and a spectrophotometer (Perkin Elmer, Lambda 25; PerkinElmer, Inc., 
Waltham, MA); the software used for the test and for calculating the results 
was WinSotax (Sotax). 
Subjects 
Seven subjects with atrophic gastritis (5 women, 2 men) were enrolled. Mean 
age ± SD was 57 ± 7 years and mean body weight 75 ± 22 kg. The mean serum 
gastrin level of the subjects was 417 pM (range 192 to 968 pM, upper normal 
limit 50 pM). Pepsinogen-1 level was below the detection threshold of 25 µg ⁄ l 
in all volunteers. A routine follow-up gastroscopy with biopsies had been 
performed on each participant within 1 year prior to the study, and chronic 
atrophic corpus gastritis without concurrent H. pylori infection had been 
confirmed histologically in all subjects. All volunteers were non-smokers and 
normal social drinkers, with an average consumption of 50 g or less of ethanol 
per week. Five of the subjects were receiving vitamin B12 substitution, 1 had 
medication for hypertension and hypercholesterolemia, and 2 had medication 
for hypothyroidism; otherwise, the volunteers were clinically healthy. None of 
the volunteers had received any antibiotics or medication that influences the 
acidity of the stomach for 1 month preceding the study. 
Study Design 
The study was approved by the ethics committee of the department of 
medicine at the Helsinki University Central Hospital, and also by the Finnish 
National Agency for Medicines. Informed consent was obtained. 
 
The study was randomized, double-blinded and placebo controlled. Each 
participant served as their own control. The two study days were separated by 
at least three days. The volunteers were admitted to the department of 
gastroenterology at Helsinki University Central Hospital, and all studies 
started between 8 and 10 AM. Volunteers were told to refrain from alcohol 
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intake for 24 hours prior, and food intake for 12 hours prior. Subjects were told 
to report any possible side effects during and after the experiments.  
 
Nasogastric intubation to a depth of 55cm (Duodenal tube Levin, CH10; 
Unomedical, Birkeroed, Denmark) was performed using Xylocain gel 
lubrication (Astrazeneca, Södertälje, Sweden) Participants were given 100ml 
water to facilitate swallowing of the tube, and location of tube was confirmed 
by aspiration of gastric contents. Participants laid on their left sides for the 
duration of the test to delay gastric emptying. Four capsules containing either 
200mg cysteine in total, or placebo were given double blindly, with 200ml 
water. Ethanol (0.3g/kg body weight) diluted in water to 15 vol% was infused 
through the nasogastric tube. Samples of gastric juice (5ml) were aspirated 
through the tube at 5-minute intervals up to 60 minutes after the ethanol 
infusion, or until aspiration was no longer successful, indicating stomach 
emptying. Samples were analysed for pH, acetaldehyde, ethanol, and cysteine 
concentrations. We measured pH using a glass electrode and a digital pH 
meter (WTW pH-521, Weilheim, Germany) 
 
Acetaldehyde concentration was analysed by headspace gas 
chromatography, as described above in the previous original publications in 
this thesis. 450µl of sample was added to 50µl 6M perchloric acid for 
acetaldehyde analysis. For ethanol analysis, the sample was diluted 1:10 in 
purified water and 500µl was transferred into headspace vials for analysis. 
Duplicate samples were analysed, and the means were used in statistical 
analysis. 
L-Cysteine analysis of gastric juice samples. 
L-cysteine concentration of gastric juice was measured by HPLC. Two parallel 
samples were prepared and analysed. 60 µl of gastric juice was measured into 
a test tube, and 30 µl of pH 7.4 phosphate-buffered saline solution (Ph.Eur.) 
and 30 µl of 20 vol% Tri-n-butylphosphine in dimethylformamide were added. 
The samples were incubated for 30 minutes at +4°C, after which 90 µl of cold 
10% trichloroacetic acid containing 1 mM Na2EDTA was added, and the 
samples were vortexed for 2 minutes and then centrifuged (10 minutes, 
2,490·g). Fifty microliters of supernatant were pipetted into a test tube 
containing 125 µl of pH 9.5 borate buffer with 4 mM Na2EDTA, 10 µl of 1.55 
M sodium hydroxide, and 50 µl of 2 mg ⁄ ml 4-Fluoro-7-Sulfobenzofurazan, 
Ammonium salt (SBD-F) solution in borate buffer. The samples were 
incubated for 60 minutes at +60°C so that a yellow derivate was formed. 
Thereafter, 150 µl of the solution was pipetted into HPLC inserts. Injection 
volume was 10 µl. The system was equipped with a Waters Model 501 piston 
pump (Waters, Milford, MA), a Waters 717 Auto-sampler, a Waters 484 
tuneable absorbance detector, and a Millennium 32 Chromatography 
Manager workstation. The isocratic mobile phase was pH 7.0 phosphate buffer 
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and methanol (95:5). The flow rate was 1 ml ⁄ min and retention time was 6 
minutes. l-cysteine concentration was determined using a fluorescence 
detector (excitation 385 nm, emission 515 nm). 
Statistical analysis 
Statistical significance was tested by Wilcoxon’s nonparametric test for paired 
samples. Correlations were tested using Spearman’s rho. A p value less than 
0.05 was considered statistically significant. Statistical analysis was carried 




Potential mechanism for calvados-related oesophageal 
cancer 
We found significantly higher mean acetaldehyde concentrations in calvados 
(1780 ± 861 µM, mean ± SEM; (range 451–3928 µM); n = 25) compared to 
other spirits (1251 ± 1155 µM (range 0–4339 µM), p < 0.05), wines (275 ± 236 
µM (range 0–536 µM), and beer and cider (233 ± 281 µM (range 0–734 µM), 
p < 0.001) (fig. 1). The highest acetaldehyde concentration of 4339 µM was 







Fig.1 Acetaldehyde concentrations on 
groups of beverages. The calvados and 
other spirits groups differ significantly from 
each other (p < 0.05), as well as from the 









There was a positive correlation between ethanol concentration and 
acetaldehyde concentration among all beverages tested (ρ = 0.748, p < 0.001; 
n=49), that persisted also when excluding wines, beers, and ciders (ρ = 0.382, 
























































Fig. 2 Scatter plot showing acetaldehyde and ethanol concentrations of all measured beverages  
Accordingly, when adjusting acetaldehyde concentration by ethanol 
concentration we found a significant difference only between calvados and 
wines. When adjusting for ethanol concentrations the mean acetaldehyde 
concentrations in farm made calvados and factory-made calvados were 18.81 








Fig. 3 Acetaldehyde content in beverages 
adjusted for ethanol concentration (mean ± 
SEM). There is a significant difference 





















































































A single sip of a strong alcoholic beverage causes 
exposure to carcinogenic concentrations of 
acetaldehyde in the oral cavity 
We found significantly higher salivary acetaldehyde concentrations at 30 
seconds after sipping calvados vs. 40% ethanol beverage both without and 
with previous alcohol ingestion (258 ± 89 vs. 122 ± 49 and 215 ± 108 vs. 128 ± 
55, calvados vs. ethanol, without and with previous alcohol ingestion, µM ± 
SD, p < 0.05, fig. 4). No difference in acetaldehyde concentration was observed 
between groups at 2, 5 and 10 minutes. At 2 minutes the mean acetaldehyde 
concentration ranged from 159 ± 66 to 192 ± 67, µM ± SD. Peak mean 
acetaldehyde concentrations were measured at 30 seconds after sipping 
calvados, and at 2 minutes after sipping 40% ethanol, where after the 
acetaldehyde concentrations decreased with time. When calculating area 
under the curve for acetaldehyde exposure, no significant differences were 
observed between groups.  
 
 
Fig. 4 Acetaldehyde concentration in saliva (mean ± SD). There is a significant difference at 
0.5minutes between calvados and ethanol (p < 0.05). 
Acetaldehyde and ethanol concentrations ± SD were higher in the control 
samples after alcohol ingestion than without it. (55 ± 32 vs. 27 ± 21, µM ± SD, 
and 12 ± 7.7 vs 2.7 ± 1.6, mM ± SD, with vs. without previous alcohol ingestion, 
acetaldehyde and ethanol concentration, p < 0.05). Apart from these control 
samples alcohol ingestion did not result in any significant differences in 
salivary acetaldehyde concentrations. 
 
Salivary ethanol concentration was over the upper limit of detection of the 













































control, after alcohol ingestion
calvados, after alcohol ingestion
ethanol, after alcohol ingestion
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concentration ranged from 83-106mM, with no significant differences 
between groups. At 10 minutes ethanol concentration was significantly higher 
after alcohol ingestion (34 ± 14 and 34 ± 13, mM ± SD) than without it (18 ± 
6.1 and 17 ± 11, mM ± SD), calvados and ethanol, p < 0.05. 
Reducing carcinogenic acetaldehyde exposure in the 
achlorhydric stomach with cysteine 
The cysteine capsules delayed the release of L-cysteine for 10-15 minutes, after 
which L-cysteine was rapidly dissolved. (fig. 5) Powdered L-cysteine was 
dissolved 100% in 5 minutes. 
 
 
Fig.5 Dissolution of L-cysteine capsules, L-cysteine granules without the capsule shell and L-
cysteine powder (dissolution % ± SD) 
No changes in gastric juice pH were found between placebo and cysteine 
administrations, and no significant change in pH was observed during the test. 





































The average acetaldehyde concentration of all samples was 2.6 times higher 
with placebo vs. cysteine (13 vs. 4.7 µM, p < 0.05, n=7). The area under the 
curve (AUC), for the 5 subjects with data up to 40 minutes, was also 
significantly larger with placebo than with cysteine (531 vs 197 µM × min, p < 
0.05, n = 5, fig. 6).  
 
 
Fig. 6 Acetaldehyde concentration (µM ± SEM) after intragastric ethanol (0.3g/kg body 
weight) and placebo or cysteine (200mg) administration in 5 subjects with atrophic gastritis. 
 
 
No significant differences in ethanol concentration existed between 
cysteine and placebo treatments. Ethanol concentration decreased steadily 
throughout the experiment (fig. 7). One volunteer reported slight joint pain 






































Fig. 7 Ethanol concentration in vol% ± SEM after intragastric ethanol (0.3g/kg body weight, 
diluted to 15 vol% in water) and placebo or cysteine (200mg) administration in 5 subjects with 
atrophic gastritis.  
L-cysteine was detected in samples following administration of the cysteine 
capsules (fig. 8.) No cysteine was detected after placebo. We found no 
significant correlation between cysteine concentration and acetaldehyde 





































Fig.8 Mean L-cysteine concentration ± SEM in gastric juice after intragastric ethanol (0.3g/kg 
body weight) and placebo or cysteine (200mg) administration in 5 subjects with atrophic 








































I – Acetaldehyde in alcoholic beverages, with emphasis 
on calvados. 
We found an abundance of acetaldehyde in calvados, and also in other strong 
alcoholic beverages. Wines, beers and ciders had lower acetaldehyde 
concentrations. In this sample of beverages acetaldehyde concentration 
correlated positively with ethanol concentration, and thus the high 
acetaldehyde concentration found in calvados is to some extent explained by 
the high alcohol concentration of farm-made calvados. However, this 
correlation should not be generalized to alcoholic beverages overall, as the 
manufacturing process largely affects acetaldehyde concentrations in 
beverages. For example, when making vodka, several rounds of distillation 
remove most if not all acetaldehyde from these types of beverages, and 
acetaldehyde levels in these are generally low (Boffetta et al. 2011). Also, 
sulphites in wines may reduce the amount of acetaldehyde freely detectable by 
our method by binding it (Liu, Pilone 2000). When adjusting for alcohol 
content in beverages, wines contained less acetaldehyde. Consequently, when 
adjusting for total alcohol consumption direct acetaldehyde exposure 
excluding acetaldehyde produced from ethanol by microbes and mucosa, is 
greater from calvados compared to wine. Far greater concentrations of 
acetaldehyde than were found in our measurements have since been found in 
other alcoholic beverages. Up to 40mM concentrations were found in grappa 
(Paiano et al. 2014). 
 
Consumption of hot calvados explained 41% of a regional peak in incidence 
of oesophageal squamous cell carcinoma in north-western France, when 
adjusting for other risk factors (Launoy et al. 1997). The mean acetaldehyde 
concentration in calvados in our study was 1780 µM, range 451-3928 µM. This 
lies well above salivary acetaldehyde concentrations measured after 
administration of a moderate dose of alcohol (19 – 143 µM, generally below 
100µM) (Homann et al. 1997, Vakevainen, Tillonen, Agarwal et al. 2000, 
Salaspuro, V., Salaspuro 2004). Salivary concentrations of acetaldehyde 
measured during cigarette smoking are somewhat higher, 261 ± 45.5 µM ± 
SEM, n=7. Combining drinking and cigarette smoking resulted in 
acetaldehyde concentrations up to 350-400µM (Salaspuro, V., Salaspuro 
2004). Even while accounting for a small dilution of calvados in saliva when 
sipped and swallowed, the resulting concentrations lie well above those 
measured during drinking and smoking.  
 
In the study by Launoy et. al., hot calvados was defined as either calvados 
with coffee, or more seldom calvados as a grog with hot water. Calvados was 
 
49 
seldom consumed alone or cold in this study population. This may explain the 
emphasis on hot calvados (Launoy et al. 1997). Any possible mucosal thermal 
damage caused by hot coffee or grog may contribute to any carcinogenic in a 
beverage taken simultaneously, and cultural drinking habits may contribute in 
this way to an individual’s risk for alcohol related upper digestive tract cancer. 
 
Our study is limited by the low number of samples from beverages other 
than calvados. The amount of calvadoses sampled – and particularly different 
farm-made calvadoses – was sufficient in regards to the scope of this study. 
The findings have been by confirmed in (Lachenmeier, Sohnius 2008), and 
similar studies on different alcoholic beverages from around the world also 
show marked variation in acetaldehyde concentrations (Lachenmeier, 
Kanteres et al. 2009, Boffetta et al. 2011, Paiano et al. 2014).  
 
We concluded that the acetaldehyde found in calvados could result in an 
increased acetaldehyde exposure and could explain the increased risk 
associated with consumption of hot calvados in France. To further examine 
this theory, we devised the experiment detailed in the second publication in 
this thesis. 
 
II - Salivary acetaldehyde concentration in vivo after 
ingestion of strong alcoholic beverages. 
We found very high concentrations of acetaldehyde in saliva immediately after 
a small sip of strong alcoholic beverage. The differences between calvados, and 
diluted ethanol were however surprisingly small, and significant only at 30 
seconds after the tasting of the beverages. Neither was there any significant 
difference in the area under the curve for acetaldehyde concentration × time. 
The mean concentrations 30s after a sip of calvados were up to 7 times higher 
than measured previously after alcohol ingestion to a BAC of 0.5 ‰. Small but 
measurable amounts of acetaldehyde were found in the control saliva samples. 
In previous studies salivary acetaldehyde without drinking or smoking has 
been zero (Homann et al. 1997, Vakevainen, Tillonen, Agarwal et al. 2000, 
Vakevainen, Tillonen, and Salaspuro 2001). This discrepancy is readily 
explained by acetaldehyde produced from the residual ethanol from the test 
run, and previous experiment as explained in the study design. 
 
In general, the acetaldehyde concentrations were higher than in previous 
studies on salivary acetaldehyde concentration after alcohol drinking. The 
ethanol concentrations in saliva immediately after oral administration of the 
alcoholic beverage are higher than concentrations distributed through the 
bloodstream. Thus, the ADH-mediated reaction is tilted by an abundance of 
substrate (ethanol) towards production of more acetaldehyde. Unfortunately, 
Discussion 
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ethanol concentrations in the 30-second and 2-minute samples were above the 
upper limit of measurement for our gas chromatograph. The study by 
(Maejima et al. 2015) is so far the only study to examine salivary acetaldehyde 
concentrations not after drinking an alcoholic beverage, but after intragastric 
infusion. Salivary acetaldehyde concentrations, which stemmed completely 
from ethanol distributed by the blood stream, were markedly low, less than 
half compared to previous studies with a similar per oral ethanol dose 
(Vakevainen, Tillonen, Agarwal et al. 2000, Vakevainen, Tillonen, and 
Salaspuro 2001, Homann et al. 1997). 
 
Acetaldehyde concentration in saliva at 30 seconds after a 5ml sip of 
calvados, containing 2400µM acetaldehyde was surprisingly low. We know 
that there is on average 0.8ml residual saliva in the mouth, and that saliva is 
secreted at a rate of 0.1ml/min when unstimulated, up to a maximum of 7 
ml/min when stimulated  (Humphrey, Williamson 2001). If we add 5ml of 
beverage and swish it around in the mouth for 5 seconds as in this study, the 
beverage is mixed with saliva and diluted by a factor of 0.86, and the resulting 
acetaldehyde concentration will be around 2100µM. Only thirty seconds after 
this we measured on average 242µM acetaldehyde in saliva, a decrease that 
cannot be explained even by assuming dilution by the maximum flow of saliva. 
Acetaldehyde is soluble in water and in lipids, and some acetaldehyde is 
presumed to diffuse into mucosal cells, and the bloodstream. At two minutes 
the acetaldehyde concentration in saliva was similar regardless of 
acetaldehyde concentration in the tasted beverage. The acetaldehyde 
concentration decreased along with the ethanol concentration over time. 
Altogether this study along with the previous studies suggest that a metabolic 
and kinetic equilibrium between acetaldehyde and ethanol is achieved, and 
that salivary acetaldehyde concentration in an individual is largely dependent 
on the prevalent ethanol concentration. 
 
The study is somewhat limited by the small number of test subjects. This 
model studying direct exposure to ethanol after a sip of alcoholic beverage 
results in more variation in salivary ethanol concentration than models with 
ingested ethanol, distributed via the blood to the mouth and other tissues and 
bodily fluids in a more predictable manner. This was overlooked when 
planning the experiments. The increased variance might have caused us to 
miss some differences in actual acetaldehyde concentration between groups. 
Also, it would have been interesting to examine sipping a solution of 
acetaldehyde, but as acetaldehyde is poisonous, we refrained from this. Since 
calvados is meant and approved for human consumption, it was deemed more 
acceptable having test subjects sip calvados although it contained 
acetaldehyde. Due to a misjudgement, in the first 2 samples, salivary ethanol 
concentrations were above the upper limit of detection of the gas 
chromatograph. This could have been avoided by reserving some saliva for 
dilution. Also, the amount of saliva given while sampling was not measured, 
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saliva was collected in a small bottle by spitting – repeatedly if necessary – 
until enough was available for pipetting 450µl for analysis. Our results were 
confirmed in a similar study using several beverages with different 
acetaldehyde concentrations (Lachenmeier, Monakhova 2011), and also in a 
study comparing ALDH2 deficient and proficient individuals (Helminen et al. 
2013).  
 
We concluded that acetaldehyde in alcoholic beverage is reflected onto 
salivary acetaldehyde concentration for a very short time immediately after 
drinking, and acetaldehyde concentration rapidly decreases to a level which is 
dependent on ethanol concentration. In a normal drinking situation, where 
repeated sips are taken over time this small peak in acetaldehyde exposure is 
repeated, and may be of significance. An equally important finding was that 
after such a sip, high levels of ethanol, and consequently acetaldehyde remain 
in saliva for at least 10 minutes, and probably up to 25 minutes, as shown by 
acetaldehyde present in the control samples. We were first to discover that 
repeated sipping could account for the major part of local acetaldehyde 
exposure (Nieminen, Salaspuro 2018). In a normal drinking situation, the 
alcoholic beverage is swallowed repeatedly, and presumably the exposure to 
high ethanol and acetaldehyde concentrations continue for some 
undetermined time. This is possibly one of the reasons for the increased risk 
for cancer caused by alcohol consumption manifesting especially in the upper 
digestive tract. 
III - Eliminating acetaldehyde from stomach using 
cysteine 
We found comparatively low concentrations of acetaldehyde in gastric juice 
after infusing a small dose of alcohol in test subjects with achlorhydric 
stomach due to atrophic gastritis. L-cysteine capsules were able to further 
reduce acetaldehyde concentration in gastric juice. The difference in 
acetaldehyde concentration was significant from 20 minutes until 40 minutes. 
According to dissolution tests on the cysteine capsules, the cysteine is released 
only after 5 - 10 minutes, which explains to some extent why acetaldehyde 
concentrations were similar in the treatment and placebo groups up to 15 
minutes. From 45 minutes onward, we were unable to acquire gastric juice 
samples from most patients, probably due to stomach emptying and statistical 
power was diminished. According to gastric juice cysteine measurements the 
selected dose of 200mg L-cysteine / capsule was adequate, and the L-cysteine 
was released in a controlled rate. The subjects were fasting during this 
experiment, and lied on their left sides, to delay gastric emptying. We don’t 
know how well the cysteine would perform in a situation where subjects are 
standing, maybe even dancing, and drinking alcohol continuously. L-cysteine 




Our results were confirmed later in two studies using similar L-cysteine 
releasing capsules (Acetium, Biohit Oyj., Helsinki, Finland). In Japan, 10 
ALDH2-deficient and 10 ALDH2-proficient volunteers were studied. 
Achlorhydria was established with a 7-day regimen of rabeprazole 10mg twice 
a day. L-cysteine capsules were able to significantly reduce acetaldehyde 
concentrations in gastric juice after ethanol infusion for up to 2 hours 
(Maejima et al. 2015). In Sweden 7 subjects with atrophic, achlorhydric 
gastritis were studied. L-Cysteine capsules were again able to reduce gastric 
juice acetaldehyde concentrations after intragastric infusion of ethanol. The 
elimination of acetaldehyde by binding to L-cysteine was further confirmed by 
detection of elevated MTCA in gastric juice after giving L-cysteine capsules 
compared to placebo (Hellstrom et al. 2017). 
 
We showed that L-cysteine capsules can be used to reduce exposure to 
acetaldehyde in stomachs of patients with achlorhydric atrophic gastritis 
during alcohol exposure. Exogenous ethanol can lead to acetaldehyde 
production in achlorhydric stomach, but there is also evidence for endogenous 
ethanol production in achlorhydria due to cimetidine use (Bode et al. 1984), 
and a slight increase in gastric juice ethanol and acetaldehyde concentrations 
were detected after intragastric glucose infusion in some patients with 
atrophic achlorhydric gastritis (Vakevainen et al. 2002). A similar dose of L-
cysteine as used in this study would probably be sufficient to bind any 
endogenously formed acetaldehyde. 
 
It remains to be determined whether L-cysteine capsules can be used to 
prevent incidence of gastric cancer. The optimal regimen of L-cysteine 
capsules is unknown and the overall health impact of such treatments is 
unknown. Although gastric cancer is among the most common causes of 
cancer death worldwide, the lesions take long time to form, and intervention 
studies would require exceedingly large study populations and long follow-up 
times. A population with severe atrophic gastritis, achlorhydria, and ALDH2-
deficiency would be an interesting place to start. 
 
Further prospects 
Oral microbial and mucosal capacity for production of acetaldehyde from 
ethanol is high, and elimination of acetaldehyde by oxidation via ALDH is low. 
This allows for accumulation of acetaldehyde in saliva. The role of ADH in 
regulating local acetaldehyde exposure is of interest, as the enzymatic reaction 
is actually favoured towards production of ethanol in hepatic ADH (Deetz et 
al. 1984). Furthermore, Yin et. al showed in 1984 that the polymorphism in 
the ADH1B gene, with the ADH1B*2 allele resulting in faster ethanol oxidation 
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in vitro also increases the rate of acetaldehyde reduction to ethanol in vitro in 
ADH1B isolated from liver. (Yin et al. 1984). However, ADH1B expression was 
not detected in tongue or gingival mucosa, whereas ADH4 was (Dong et al. 
1996). Acetaldehyde reduction in mucosal ADH:s have not been studied, and 
research in humans has focused on the reaction towards acetaldehyde, as the 
main function of ADH and ALDH in the alcohol drinking human is to 
metabolize ethanol to acetaldehyde and further to acetate. Ethanol oxidation 
by ADH is inhibited by the substrate, acetaldehyde. In liver acetaldehyde is 
effectively removed by ALDH, and substrate inhibition is of little or no 
significance. It is possible that the physiological role of ADH in digestive tract 
mucosa is to reduce acetaldehyde to ethanol, which can then be transported to 
the liver for elimination. The role of ADH in regulation of acetaldehyde 
concentration in the upper digestive tract warrants further research in light of 
this hypothesis, and especially considering the association of ADH1 
polymorphisms with upper digestive tract cancer risk, as discussed in the 
review of the literature. 
 
From our finding that acetaldehyde in calvados is rapidly removed from 
saliva it appears that mechanisms for acetaldehyde removal in the upper 
digestive tract are quite effective, only impaired by exposure to the copious 
amounts of ethanol available in saliva when drinking. The significance of 
acetaldehyde in foods without ethanol, or with low ethanol concentrations is 
not known.  
 
High acetaldehyde concentrations can be found in fruits and yoghurts, yet 
no compelling epidemiological evidence exists for the carcinogenicity of fruits 
or yoghurts. Acetaldehyde has been found in citrus juices in concentrations up 
to 5000µM (Lund et al. 1981), and in ripening apples rising from 1800 µM to 
15000µM (Karaoulanis, Dilley 1993). In a large German survey clearly lower 
acetaldehyde concentrations were found, where the maximum acetaldehyde 
content in an apple was 2.39mg/kg (~50µM) and in a banana 18.27 mg/kg 
(~400µM) (Uebelacker, Lachenmeier 2011). Acetaldehyde is the compound 
that contributes most to the typical flavour of yoghurt, and good flavoured 
yoghurt is said to result when “proper” levels of 500-900µM are achieved 
(Cheng 2010). In the German survey acetaldehyde concentrations in yoghurts 
ranged from 2.40mg/kg to 17.42mg/kg (~50 to 400µM) (Uebelacker, 
Lachenmeier 2011).  Consumption of fermented dairy food was associated 
with a decreased overall cancer risk in a recent meta-analysis, including 
oesophageal cancer and oropharyngeal cancer (Zhang, K. et al. 2018). 
Consumption of yoghurt, from less than once a week to daily was associated 
with a decreased risk for upper aerodigestive tract cancer, with OR:s ranging 
from 0.67 to 0.73 (Kawakita et al. 2012). There is one study from Iran where 
daily consumption of yogurt was associated with an increased risk for gastric 
cancer (OR 16.26; 95%CI 2.10 - 125.73) (Somi et al. 2015). Consumption of 
fruit is associated with a decreased risk for oral (Pavia et al. 2006), 
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oesophageal and gastric cancer (Abnet et al. 2015). Overall there is little 
evidence that acetaldehyde is carcinogenic to humans when not associated 
with consumption of alcoholic beverages. 
 
Future topics for research suggested are developing and using markers of 
acetaldehyde exposure, such as the acetaldehyde-DNA adduct N2-
ethylidenedeoxyguanosine to estimate exposure of DNA to acetaldehyde from 
different sources, whether through metabolism from ethanol, or directly from 
acetaldehyde in food, beverages, and cigarette smoke. Systematic 
measurement of ethanol and acetaldehyde content in foods is suggested in 
order to better asses the acetaldehyde exposure from acetaldehyde in non-
alcoholic foods and beverages. These markers could also be used to further 





The main findings in this thesis are: 
 
1. Acetaldehyde is found in different alcoholic beverages, and in some, at 
high concentrations which may contribute to mucosal acetaldehyde 
exposure. 
2. Acetaldehyde present in alcoholic beverages contributes to 
acetaldehyde exposure in the oral cavity after a single sip of beverage. 
After each sip, ethanol remains in saliva for up to ten minutes in 
concentrations that allow local formation of mutagenic acetaldehyde. 
Thus, the major part of acetaldehyde exposure associating with alcohol 
drinking stems from rapid oxidation of ethanol in the mouth. 
3. Slow release L-cysteine capsules can be used to reduce acetaldehyde 
concentration in achlorhydric gastric juice after intragastric ethanol 
infusion. 
 
There is compelling epidemiological, genetic and biochemical evidence that 
local acetaldehyde exposure from ethanol oxidation in the upper digestive 
tract contributes to the development of cancer. This thesis provides further 
mechanistic insight in the kinetics of acetaldehyde formation and elimination 
in the mouth and introduces the concept of eliminating acetaldehyde in 
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